Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription

Articles published in Blood

Retrieve available abstracts of 562 articles:
HTML format

Single Articles

    June 2022
  1. QIU L, Quesada AE
    Plasma cell leukemia with small cell morphology.
    Blood. 2022;139:3667.

  2. Al-Sawaf O, Lilienweiss E, Bahlo J, et al. High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia. Blood. 2020;135(11):866-870.
    Blood. 2022;139:3669.

  3. TANAKA A, Nakano TA, Nomura M, Yamazaki H, et al
    Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia.
    Blood. 2022 Jun 16. pii: 485590. doi: 10.1182/blood.2021015325.
    PubMed     Abstract available

    Why B(-)other? About the gap of unknowns in ALL.
    Blood. 2022;139:3455-3457.

  5. FREEMAN SD, Valk P
    Transplant in older adults with AML: genomic wheat and chaff.
    Blood. 2022;139:3459-3461.

  6. Genetics and outcome in older AML transplant.
    Blood. 2022;139:3559.

  7. YEUNG DT, Shanmuganathan N, Hughes TP
    Asciminib: a new therapeutic option in chronic-phase CML with treatment failure.
    Blood. 2022;139:3474-3479.
    PubMed     Abstract available

  8. PASSET M, Kim R, Gachet S, Sigaux F, et al
    Concurrent CDX2 cis-deregulation and UBTF::ATXN7L3 fusion define a novel high-risk subtype of B-cell ALL.
    Blood. 2022;139:3505-3518.
    PubMed     Abstract available

  9. MURDOCK HM, Kim HT, Denlinger N, Vachhani P, et al
    Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML.
    Blood. 2022;139:3546-3557.
    PubMed     Abstract available

  10. CHEMINANT M, Lhermitte L, Bruneau J, Sicard H, et al
    KIR3DL2 contributes to the typing of acute-type adult T-cell leukemia and is a potential therapeutic target.
    Blood. 2022 Jun 10. pii: 485527. doi: 10.1182/blood.2022016765.
    PubMed     Abstract available

  11. ALVAREZ S, da Silva Almeida AC, Albero R, Biswas M, et al
    Functional mapping of PHF6 complexes in chromatin remodeling, replication dynamics, and DNA repair.
    Blood. 2022;139:3418-3429.
    PubMed     Abstract available

  12. PERL AE, Larson RA, Podoltsev NA, Strickland S, et al
    Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.
    Blood. 2022;139:3366-3375.
    PubMed     Abstract available

  13. LI Y, Yang X, Sun Y, Li Z, et al
    The Impact of T cell Immunity on Chemotherapy Response in Childhood Acute Lymphoblastic Leukemia.
    Blood. 2022 Jun 8. pii: 485490. doi: 10.1182/blood.2021014495.
    PubMed     Abstract available

  14. ROBIN M, de Wreede LC, Padron E, Bakunina K, et al
    Role of Allogeneic Transplantation In Chronic Myelomonocytic Leukemia: An International Collaborative Analysis.
    Blood. 2022 Jun 6. pii: 485477. doi: 10.1182/blood.2021015173.
    PubMed     Abstract available

  15. SONG H, Liu Y, Tan Y, Zhang Y, et al
    Recurrent non-coding somatic and germline WT1 variants converge to disrupt MYB binding in acute promyelocytic leukemia.
    Blood. 2022 Jun 2. pii: 485457. doi: 10.1182/blood.2021014945.
    PubMed     Abstract available

  16. ROGERS KA, Woyach JA
    A CAPTIVATE-ing new regimen for CLL.
    Blood. 2022;139:3229-3230.

  17. FERNANDEZ-SEVILLA LM, Valencia J, Ortiz-Sanchez P, Fraile-Ramos A, et al
    High BMP4 expression in low/intermediate risk BCP-ALL identifies children with poor outcomes.
    Blood. 2022;139:3303-3313.
    PubMed     Abstract available

  18. TAM CS, Allan JN, Siddiqi T, Kipps TJ, et al
    Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.
    Blood. 2022;139:3278-3289.
    PubMed     Abstract available

    May 2022

  19. Genomic landscape of T-LGL leukemia.
    Blood. 2022;139:3100.

  20. SEMENZATO G, Zambello R
    Interrogating molecular genetics to refine LGLL classification.
    Blood. 2022;139:3002-3004.

  21. LAUKKANEN S, Bacquelaine Veloso A, Yan C, Oksa L, et al
    Combination therapies to inhibit LCK tyrosine kinase and mTOR signaling in T-cell Acute Lymphoblastic Leukemia.
    Blood. 2022 May 11. pii: 485213. doi: 10.1182/blood.2021015106.
    PubMed     Abstract available

  22. BIEDERSTADT A, Rezvani K
    How I treat high-risk acute myeloid leukemia using pre-emptive adoptive cellular immunotherapy.
    Blood. 2022 May 5. pii: 485176. doi: 10.1182/blood.2021012411.
    PubMed     Abstract available

  23. Tomizawa D, Miyamura T, Imamura T, et al. A risk-stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial. Blood. 2020;136(16):1813-1823.
    Blood. 2022;139:2848.

  24. LI L, Kim JH, Lu W, Williams DM, et al
    HMGA1 chromatin regulators induce transcriptional networks involved in GATA2 and proliferation during MPN progression.
    Blood. 2022;139:2797-2815.
    PubMed     Abstract available

  25. TYAGI A, Ly S, El-Dana F, Yuan B, et al
    Evidence supporting a role for the immune checkpoint protein B7-H3 in NK cell-mediated cytotoxicity against AML.
    Blood. 2022;139:2782-2796.
    PubMed     Abstract available

  26. FREY NV
    Approval of brexucabtagene autoleucel for adults with relapsed and refractory acute lymphocytic leukemia.
    Blood. 2022 May 4. pii: 485154. doi: 10.1182/blood.2021014892.
    PubMed     Abstract available

  27. MACIOCIA PM, Wawrzyniecka PA, Maciocia NC, Burley A, et al
    Anti-CCR9 Chimeric Antigen Receptor T cells for T Cell Acute Lymphoblastic Leukemia.
    Blood. 2022 May 4. pii: 485152. doi: 10.1182/blood.2021013648.
    PubMed     Abstract available

    April 2022
  28. CHEN Z, Simon-Molas H, Cretenet G, Valle-Argos B, et al
    Characterization of metabolic alterations of Chronic Lymphocytic Leukemia in the lymph node microenvironment.
    Blood. 2022 Apr 29. pii: 485126. doi: 10.1182/blood.2021013990.
    PubMed     Abstract available

    New hope to prevent ALL relapse after transplant.
    Blood. 2022;139:2580-2581.

  30. ZHAO Y, Wang E
    Pure erythroid leukemia evolved from JAK2V617F-positive polycythemia vera: blast phase transformation along erythroid line.
    Blood. 2022;139:2574.

    Firing up chromatin to forge T-ALL.
    Blood. 2022;139:2418-2420.

  32. ANTOSZEWSKI M, Fournier N, Ruiz Buendia GA, Lourenco J, et al
    Tcf1 is essential for initiation of oncogenic Notch1-driven chromatin topology in T-ALL.
    Blood. 2022;139:2483-2498.
    PubMed     Abstract available

  33. DUPLOYEZ N, Largeaud L, Duchmann M, Kim R, et al
    Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study.
    Blood. 2022 Apr 20. pii: 485005. doi: 10.1182/blood.2021015328.
    PubMed     Abstract available

  34. LEWIS AC, Pope VS, Tea MN, Li M, et al
    Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia.
    Blood. 2022 Apr 20. pii: 485003. doi: 10.1182/blood.2021013277.
    PubMed     Abstract available

  35. WELCH JS
    TP53 and the star-crossed lovers MDS and AML.
    Blood. 2022;139:2265-2266.

  36. TASHAKORI M, Kadia TM, Loghavi S, Daver NG, et al
    TP53 Copy Number and Protein Expression Inform Mutation Status across Risk Categories in Acute Myeloid Leukemia.
    Blood. 2022 Apr 7. pii: 484631. doi: 10.1182/blood.2021013983.
    PubMed     Abstract available

    Immunity in CLL: corrupt at inception?
    Blood. 2022;139:2104-2105.

  38. DEPASQUALE EAK, van Galen P
    Plasticity and immune evasion in childhood ALL.
    Blood. 2022;139:2096-2097.

  39. PURROY N, Tong YE, Lemvigh CK, Cieri N, et al
    Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib.
    Blood. 2022;139:2252-2256.

  40. ROBOZ GJ, Ravandi F, Wei AH, Dombret H, et al
    Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status.
    Blood. 2022;139:2145-2155.
    PubMed     Abstract available

  41. LEAHY AB, Devine KJ, Li Y, Liu H, et al
    Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy.
    Blood. 2022;139:2173-2185.
    PubMed     Abstract available

    March 2022
  42. BELLUSCI L, Grubbs G, Srivastava P, Nemeth MJ, et al
    Neutralization of SARS-CoV-2 Omicron after vaccination of myelodysplastic syndromes and acute myeloid leukemia patients.
    Blood. 2022 Mar 28. pii: 484507. doi: 10.1182/blood.2022016087.

  43. QI Y, Zhao M, Hu Y, Wang Y, et al
    Efficacy and safety of CD19-specific CAR T-cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL.
    Blood. 2022 Mar 25. pii: 484499. doi: 10.1182/blood.2021013733.
    PubMed     Abstract available

  44. WANG HY, Heyman BM
    Annexin A1- but CD10+ hairy cell leukemia.
    Blood. 2022;139:1924.

  45. KATER AP, Melenhorst JJ
    Do CARs finally hit the CLL road?
    Blood. 2022;139:1775-1776.

  46. SIDDIQI T, Soumerai JD, Dorritie KA, Stephens DM, et al
    Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL.
    Blood. 2022;139:1794-1806.
    PubMed     Abstract available

  47. BUCHMANN S, Schrappe M, Baruchel A, Biondi A, et al
    Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium.
    Blood. 2022;139:1785-1793.
    PubMed     Abstract available

  48. BEWERSDORF JP, Patel KK, Goshua G, Shallis RM, et al
    Cost-effectiveness of liposomal cytarabine/daunorubicin in patients with newly diagnosed acute myeloid leukemia.
    Blood. 2022;139:1766-1770.

  49. PARAS G, Morsink LM, Othus M, Milano F, et al
    Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML.
    Blood. 2022;139:1694-1706.
    PubMed     Abstract available

  50. BEDNARSKI JJ, Zimmerman C, Berrien-Elliott MM, Foltz JA, et al
    Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant.
    Blood. 2022;139:1670-1683.
    PubMed     Abstract available

    Memory NK cells to forget relapsed AML.
    Blood. 2022;139:1607-1608.

    Toward consensus on geriatric assessment in AML.
    Blood. 2022;139:1605-1606.

  53. MIN GJ, Cho BS, Park SS, Park S, et al
    Geriatric assessment predicts nonfatal toxicities and survival for intensively treated older adults with AML.
    Blood. 2022;139:1646-1658.
    PubMed     Abstract available

  54. TRACY SI, Venkatesh H, Hekim C, Heltemes Harris LM, et al
    Combining nilotinib and PD-L1 blockade reverses CD4+ T-cell dysfunction and prevents relapse in acute B-cell leukemia.
    Blood. 2022 Mar 11. pii: 484383. doi: 10.1182/blood.2021015341.
    PubMed     Abstract available

    Targeting vulnerabilities of adult T-cell leukemia.
    Blood. 2022;139:1435.

  56. NEDUMANNIL R, Juneja S
    Pseudo-Chediak-Higashi inclusions in BCR::ABL1-like B-lymphoblastic leukemia with IGH::EPOR rearrangement.
    Blood. 2022;139:1598.

  57. Silva O, Kurzer J. Nonleukemic T/B mixed phenotype acute leukemia with PHF6 and NOTCH1 mutations. Blood. 2021;138(9):818.
    Blood. 2022;139:1602.

  58. MARTI G
    Premonoclonal B-cell lymphocytosis: the CLL cell of origin.
    Blood. 2022;139:1436-1437.

  59. STIVERS N, Afify Z
    Pediatric B-acute lymphoblastic leukemia presenting with a mass: an underrecognized association.
    Blood. 2022;139:1423.

  60. Awada H, Durmaz A, Gurnari C, et al. Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia. Blood. 2021;138(19):1885-1895.
    Blood. 2022;139:1424-1425.

  61. KWOK M, Stankovic T
    The three musketeers: uniting against CLL.
    Blood. 2022;139:1264-1265.

    PP2A activation targets AML stem cells.
    Blood. 2022;139:1267-1269.

    February 2022
  63. MAITI A, Daver NG
    A nonstick marrow may help to fry leukemia.
    Blood. 2022;139:1119-1121.

  64. Lulla PD, Naik S, Vasileiou S, et al. Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant. Blood. 2021;137(19):2585-2597.
    Blood. 2022;139:1257.

  65. BROWN AL
    And the germline beat (AML) goes on.
    Blood. 2022;139:1126-1128.

  66. BERRIEN-ELLIOTT MM, Becker-Hapak M, Cashen AF, Jacobs M, et al
    Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy.
    Blood. 2022;139:1177-1183.
    PubMed     Abstract available

  67. YANG F, Long N, Anekpuritanang T, Bottomly D, et al
    Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML.
    Blood. 2022;139:1208-1221.
    PubMed     Abstract available

  68. BLOMBERY P, Lew TE, Dengler MA, Thompson ER, et al
    Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL.
    Blood. 2022;139:1198-1207.
    PubMed     Abstract available

  69. SIPOL A, Hameister E, Xue B, Hofstetter J, et al
    MondoA drives malignancy in B-ALL through enhanced adaptation to metabolic stress.
    Blood. 2022;139:1184-1197.
    PubMed     Abstract available

  70. KIMURA S, Montefiori L, Iacobucci I, Zhao Y, et al
    Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia.
    Blood. 2022 Feb 22. pii: 484108. doi: 10.1182/blood.2022015444.
    PubMed     Abstract available

    Adult T-cell leukemia: genomic analysis.
    Blood. 2022;139:953-954.

  72. YOU X, Liu F, Binder M, Vedder A, et al
    Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation.
    Blood. 2022;139:1066-1079.
    PubMed     Abstract available

  73. CAZAUBIEL T, Leleu X, Perrot A, Manier S, et al
    Primary Plasma Cell Leukemia displaying t(11;14) have specific genomic, transcriptional and clinical feature.
    Blood. 2022 Feb 16. pii: 484066. doi: 10.1182/blood.2021014968.
    PubMed     Abstract available

  74. FALINI B, De Carolis L, Tiacci E
    How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors.
    Blood. 2022 Feb 10. pii: 483952. doi: 10.1182/blood.2021013502.
    PubMed     Abstract available

  75. WILL B
    Fighting AML with its own weapons.
    Blood. 2022;139:807-809.

  76. MILL CP, Fiskus W, DiNardo CD, Birdwell C, et al
    Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2.
    Blood. 2022;139:907-921.
    PubMed     Abstract available

  77. HEIKAMP EB, Henrich JA, Perner F, Wong EM, et al
    The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML.
    Blood. 2022;139:894-906.
    PubMed     Abstract available

  78. NAIK S, Vasileiou S, Tzannou I, Kuvalekar M, et al
    Donor-Derived Multiple Leukemia Antigen Specific T-cell Therapy to Prevent Relapse Post-Transplant in Patients with ALL.
    Blood. 2022 Feb 8. pii: 483888. doi: 10.1182/blood.2021014648.
    PubMed     Abstract available

  79. LV K, Tong W
    Waking up CML leukemia stem cells for the kill.
    Blood. 2022;139:647-648.

  80. WANG XQ, McGinnis E
    Megakaryocytic emperipolesis as a dyshematopoietic feature in acute myeloid leukemia with inv(16).
    Blood. 2022;139:798.

  81. BHAT SA, Woyach JA
    Boosting BNT162b2 vaccine efficacy in CLL.
    Blood. 2022;139:639-640.

  82. DEAGLIO S, Vaisitti T
    A new taxonomy for splenic marginal zone lymphoma.
    Blood. 2022;139:644-645.

  83. HERISHANU Y, Rahav G, Levi S, Braester A, et al
    Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination.
    Blood. 2022;139:678-685.
    PubMed     Abstract available

  84. DAVIDS MS, Rogers KA, Tyekucheva S, Wang Z, et al
    Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome.
    Blood. 2022;139:686-689.
    PubMed     Abstract available

  85. SASAKI K, Yamauchi T, Semba Y, Nogami J, et al
    Genome-wide CRISPR-Cas9 screen identifies rationally designed combination therapies for CRLF2-rearranged Ph-like ALL.
    Blood. 2022;139:748-760.
    PubMed     Abstract available

  86. GROB T, Al Hinai AS, Sanders MA, Kavelaars F, et al
    Blood. 2022 Feb 2. pii: 483799. doi: 10.1182/blood.2021014472.
    PubMed     Abstract available

    January 2022
  87. PETERS FS, Kater AP
    Increasing CART cell engine performance in CLL.
    Blood. 2022;139:473-474.

  88. FUNK CR, Wang S, Chen KZ, Waller A, et al
    PI3Kdelta/gamma inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity.
    Blood. 2022;139:523-537.
    PubMed     Abstract available

  89. MAN CH, Mercier FE, Liu N, Dong W, et al
    Proton export alkalinizes intracellular pH and reprograms carbon metabolism to drive normal and malignant cell growth.
    Blood. 2022;139:502-522.
    PubMed     Abstract available

  90. ABRAHAM IE, Rauscher GH, Patel AA, Pearse W, et al
    Structural Racism is a Mediator of Disparities in Acute Myeloid Leukemia Outcomes.
    Blood. 2022 Jan 21. pii: 483615. doi: 10.1182/blood.2021012830.
    PubMed     Abstract available

  91. LEE EJ, Bussel JB
    An "ATRA-ctive" new treatment of ITP?
    Blood. 2022;139:307-308.

  92. SOMMERKAMP P, Trumpp A
    Driving differentiation: targeting APA in AML.
    Blood. 2022;139:317-319.

    T/myeloid MPAL: origin and pathogenesis.
    Blood. 2022;139:313-315.

  94. AARAKAKI H, Karube K
    Small-cell pattern of DUSP22 rearranged ALK-negative anaplastic large-cell lymphoma with leukemic phase.
    Blood. 2022;139:465.

  95. ESTEY E, Hasserjian RP, Dohner H
    Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal.
    Blood. 2022;139:323-332.
    PubMed     Abstract available

    Road to RIO-kinase 2 for AML therapy.
    Blood. 2022;139:156-157.

  97. WANG W, Hu Z
    Leukocytosis with left-shifted myeloid maturation in a peripheral blood specimen: a clue to the lymphoid blast phase of CML.
    Blood. 2022;139:305.

  98. BRENDOLAN A, Russo V
    Targeting cholesterol homeostasis in hematopoietic malignancies.
    Blood. 2022;139:165-176.
    PubMed     Abstract available

  99. FUJIHARA M, Sakata R, Yoshida N, Ozasa K, et al
    Incidence of lymphoid neoplasms among atomic bomb survivors by histological subtype, 1950 to 1994.
    Blood. 2022;139:217-227.
    PubMed     Abstract available

  100. CHEON H, Xing JC, Moosic KB, Ung J, et al
    Genomic Landscape of TCR Alpha-Beta and TCR Gamma-Delta T-Large Granular Lymphocyte Leukemia.
    Blood. 2022 Jan 11. pii: 483429. doi: 10.1182/blood.2021013164.
    PubMed     Abstract available

  101. ZHANG YH, Han X
    Acute promyelocytic leukemia with Chediak-Higashi like giant granules.
    Blood. 2022;139:149.

    CEBPA mutations in AML: site matters.
    Blood. 2022;139:6-7.

  103. YOUNG PE, Medeiros LJ
    Unexpected myeloid sarcoma of the tonsil in a patient without a history of hematological neoplasm.
    Blood. 2022;139:148.

    December 2021
  104. VOLK A
    Ticket to divide: m6A reader YTHDC1 drives acute myeloid leukemia proliferation.
    Blood. 2021;138:2748-2750.

  105. MORENO C, Mora A
    MRD in CLL: some answers, many questions.
    Blood. 2021;138:2746-2747.

  106. TRAN A, Wong M
    Atypical CML with mutated SRSF2, ASXL1, CSF3R, and MPL.
    Blood. 2021;138:2890.

  107. WANG XV, Hanson CA, Tschumper RC, Lesnick CE, et al
    Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib.
    Blood. 2021;138:2810-2827.
    PubMed     Abstract available

  108. SHENG Y, Wei J, Yu F, Xu H, et al
    A critical role of nuclear m6A reader YTHDC1 in leukemogenesis by regulating MCM complex-mediated DNA replication.
    Blood. 2021;138:2838-2852.
    PubMed     Abstract available

  109. CAI H, Kondo M, Sandhow L, Xiao P, et al
    Critical Role of Lama4 for Hematopoiesis Regeneration and Acute Myeloid Leukemia Progression.
    Blood. 2021 Dec 27. pii: 483253. doi: 10.1182/blood.2021011510.
    PubMed     Abstract available

    NPM1: not present? Mark!
    Blood. 2021;138:2602-2603.

  111. AL-SAWAF O, Fischer K
    TP53 mutations in CLL: does frequency matter?
    Blood. 2021;138:2600-2601.

  112. UY GL
    Turning AML targets inside out.
    Blood. 2021;138:2598-2599.

  113. TEN HACKEN E, Wu CJ
    Understanding CLL biology through mouse models of human genetics.
    Blood. 2021;138:2621-2631.
    PubMed     Abstract available

  114. RIGOLIN GM, Del Giudice I, Bardi A, Melandri A, et al
    Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study.
    Blood. 2021;138:2727-2730.

  115. MARTELLI MP, Rossi R, Venanzi A, Meggendorfer M, et al
    Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML.
    Blood. 2021;138:2696-2701.
    PubMed     Abstract available

  116. AUGSBERGER C, Hanel G, Xu W, Pulko V, et al
    Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody.
    Blood. 2021;138:2655-2669.
    PubMed     Abstract available

  117. MALCIKOVA J, Pavlova S, Barbara KV, Radova L, et al
    Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options.
    Blood. 2021;138:2670-2685.
    PubMed     Abstract available

  118. GABALLA MR, Banerjee PP, Milton DR, Jiang X, et al
    Blinatumomab Maintenance After Allogeneic Hematopoietic Cell Transplantation for B-lineage Acute Lymphoblastic Leukemia.
    Blood. 2021 Dec 16. pii: 483090. doi: 10.1182/blood.2021013290.
    PubMed     Abstract available

  119. SHOPSOWITZ KE, Slack GW
    B-lymphoblastic lymphoma presenting as a primary breast mass with periductal invasion.
    Blood. 2021;138:2593.

  120. SIVINA M, Kim E, Wierda WG, Ferrajoli A, et al
    Ibrutinib induces durable remissions in treatment-naive patients with CLL and 17p deletion and/or TP53 mutations.
    Blood. 2021;138:2589-2592.

  121. TONC E, Takeuchi Y, Chou C, Xia Y, et al
    Unexpected suppression of tumorigenesis by c-MYC via TFAP4-dependent restriction of stemness in B lymphocytes.
    Blood. 2021;138:2526-2538.
    PubMed     Abstract available

  122. HUBER H, Edenhofer S, von Tresckow J, Robrecht S, et al
    Phase 2 study of obinutuzumab (GA-101), ibrutinib and venetoclax (CLL2-GIVe) in patients with untreated high-risk chronic lymphocytic leukemia.
    Blood. 2021 Dec 15. pii: 483086. doi: 10.1182/blood.2021013208.
    PubMed     Abstract available

    The more complex, the worse outcome in CLL.
    Blood. 2021;138:2305-2307.

  124. THAKRAL B, Lin P
    Acute myeloid leukemia with erythroid and megakaryocytic differentiation associated with Down syndrome.
    Blood. 2021;138:2446.

  125. HITZLER J, Alonzo T, Gerbing R, Beckman A, et al
    High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial.
    Blood. 2021;138:2337-2346.
    PubMed     Abstract available

  126. KITTAI AS, Miller C, Goldstein D, Huang Y, et al
    The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib.
    Blood. 2021;138:2372-2382.
    PubMed     Abstract available

  127. LI Y, Xie X, Jie Z, Zhu L, et al
    DYRK1a mediates BAFF-induced noncanonical NF-kappaB activation to promote autoimmunity and B-cell leukemogenesis.
    Blood. 2021;138:2360-2371.
    PubMed     Abstract available

  128. WEEKS LD, Marinac CR, Redd RA, Abel GA, et al
    Age-related Diseases of Inflammation in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia.
    Blood. 2021 Dec 7. pii: 482919. doi: 10.1182/blood.2021014418.

  129. CHEN C, Yu W, Alikarami F, Qiu Q, et al
    Single-cell multiomics reveals increased plasticity, resistant populations and stem-cell-like blasts in KMT2A-rearranged leukemia.
    Blood. 2021 Dec 5. pii: 482898. doi: 10.1182/blood.2021013442.
    PubMed     Abstract available

  130. BHATIA R
    Fattening up FLT3-ITD for the kill.
    Blood. 2021;138:2158-2159.

    November 2021
    MLL-AF4+ infant leukemia: a microRNA affair.
    Blood. 2021;138:2014-2015.

  132. JACOBS JW, Siddon AJ
    Concurrent COVID-19 and babesiosis in an older, splenectomized patient.
    Blood. 2021;138:2154.

  133. REA D, Mauro MJ, Boquimpani C, Minami Y, et al
    A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.
    Blood. 2021;138:2031-2041.
    PubMed     Abstract available

  134. ROSSI M, Meggendorfer M, Zampini M, Tettamanti M, et al
    Clinical relevance of clonal hematopoiesis in persons aged >/=80 years.
    Blood. 2021;138:2093-2105.
    PubMed     Abstract available

  135. MARCAULT C, Zhao LP, Maslah N, Verger E, et al
    Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms.
    Blood. 2021;138:2142-2148.

  136. ISHIO T, Kumar S, Shimono J, Daenthanasanmak A, et al
    Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in Adult T-cell leukemia/lymphoma.
    Blood. 2021 Nov 24. pii: 482776. doi: 10.1182/blood.2021012734.
    PubMed     Abstract available

  137. ZHONG W, Cao X, Pan G, Niu Q, et al
    ORP4L is a prerequisite for the induction of T-cell leukemogenesis associated with human T-cell leukemia virus 1.
    Blood. 2021 Nov 19. pii: 482705. doi: 10.1182/blood.2021013579.
    PubMed     Abstract available

  138. GOSWAMI S, Mani R, Nunes J, Chiang CL, et al
    PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in Acute Myeloid Leukemia.
    Blood. 2021 Nov 17. pii: 482661. doi: 10.1182/blood.2020010344.
    PubMed     Abstract available

  139. ZHAO H, Pomicter AD, Eiring AM, Franzini A, et al
    MS4A3 Promotes Differentiation in Chronic Myeloid Leukemia by Enhancing Common beta Chain Cytokine Receptor Endocytosis.
    Blood. 2021 Nov 15. pii: 477970. doi: 10.1182/blood.2021011802.
    PubMed     Abstract available

  140. THOMAS D
    Machine learning finds new AML subtypes.
    Blood. 2021;138:1790-1792.

  141. DE BOCK CE, Cools J
    BETter insight into PRC2-mutated T-ALL.
    Blood. 2021;138:1787-1788.

  142. CHOI MY
    Improving the outlook for TP53-aberrant CLL.
    Blood. 2021;138:1785-1786.

  143. ANDRIEU GP, Kohn M, Simonin M, Smith CL, et al
    PRC2 loss of function confers a targetable vulnerability to BET proteins in T-ALL.
    Blood. 2021;138:1855-1869.
    PubMed     Abstract available

  144. CRAMER P, Tausch E, von Tresckow J, Giza A, et al
    Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.
    Blood. 2021;138:1805-1816.
    PubMed     Abstract available

  145. MHIBIK M, Gaglione EM, Eik D, Kendall EK, et al
    BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL.
    Blood. 2021;138:1843-1854.
    PubMed     Abstract available

  146. LANGERBEINS P, Zhang C, Robrecht S, Cramer P, et al
    The CLL12 trial: Ibrutinib versus placebo in treatment-naive, early stage chronic lymphocytic leukemia.
    Blood. 2021 Nov 10. pii: 477942. doi: 10.1182/blood.2021010845.
    PubMed     Abstract available

  147. HASLE H, Kline RM, Kjeldsen E, Nik-Abdul-Rashid NF, et al
    Germline GATA1s generating mutations predispose to leukemia with acquired trisomy 21 and Down syndrome-like phenotype.
    Blood. 2021 Nov 10. pii: 477943. doi: 10.1182/blood.2021011463.
    PubMed     Abstract available

  148. FENG Y, Feng W
    Numerous ring sideroblasts in chronic neutrophilic leukemia.
    Blood. 2021;138:1783.

  149. HERISHANU Y, Perry C
    COVID-19 in patients with CLL: how can we change the odds?
    Blood. 2021;138:1652-1653.

  150. ROEKER LE, Eyre TA, Thompson MC, Lamanna N, et al
    COVID-19 in patients with CLL: improved survival outcomes and update on management strategies.
    Blood. 2021;138:1768-1773.

  151. HEUSER M, Freeman SD, Ossenkoppele GJ, Buccisano F, et al
    2021 Update Measurable Residual Disease in Acute Myeloid Leukemia: European LeukemiaNet Working Party Consensus Document.
    Blood. 2021 Nov 1. pii: 477736. doi: 10.1182/blood.2021013626.
    PubMed     Abstract available

    October 2021
  152. CARTER BZ, Tao W, Mak PY, Ostermann LB, et al
    Menin inhibition decreases Bcl-2 and synergizes with venetoclax in NPM1/FLT3-mutated AML.
    Blood. 2021;138:1637-1641.

  153. KOGURE Y, Kameda T, Koya J, Yoshimitsu M, et al
    Whole-genome landscape of adult T-cell leukemia/lymphoma.
    Blood. 2021 Oct 25. pii: S0006-4971(21)01784-5. doi: 10.1182/blood.2021013568.
    PubMed     Abstract available

  154. SCHNOEDER TM, Schwarzer A, Jayavelu AK, Hsu CJ, et al
    PLCG1 is required for AML1-ETO leukemia stem cell self-renewal.
    Blood. 2021 Oct 25. pii: S0006-4971(21)01783-3. doi: 10.1182/blood.2021012778.
    PubMed     Abstract available

  155. YASUDA T, Sanada M, Kawazu M, Kojima S, et al
    Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of CDX2 and IDH1/2 mutations.
    Blood. 2021 Oct 25. pii: S0006-4971(21)01785-7. doi: 10.1182/blood.2021011921.
    PubMed     Abstract available

  156. ZHAO Y, Wang E
    Plasmablastic myeloma/leukemia variant of monomorphic posttransplant lymphoproliferative disorder.
    Blood. 2021;138:1510.

  157. HAUER J, Fischer U, Borkhardt A
    Toward prevention of childhood ALL by early-life immune training.
    Blood. 2021;138:1412-1428.
    PubMed     Abstract available

  158. JEBARAJ BMC, Muller A, Dheenadayalan RP, Endres S, et al
    Evaluation of vecabrutinib as a model for non-covalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia.
    Blood. 2021 Oct 18. pii: 477372. doi: 10.1182/blood.2021011516.
    PubMed     Abstract available

  159. KOLIJN PMM, Saberi Hosnijeh F, Spath F, Hengeveld PJ, et al
    Blood. 2021 Oct 18. pii: 477373. doi: 10.1182/blood.2021012890.
    PubMed     Abstract available

  160. TRINH BQ, Ummarino S, Zhang Y, Ebralidze AK, et al
    Myeloid lncRNA LOUP mediates opposing regulatory effects of RUNX1 and RUNX1-ETO in t(8;21) AML.
    Blood. 2021;138:1331-1344.
    PubMed     Abstract available

  161. FISHMAN H, Madiwale S, Geron I, Bari V, et al
    ETV6-NCOA2 fusion induces T/Myeloid mixed-phenotype leukemia by transformation of non-thymic hematopoietic progenitors.
    Blood. 2021 Oct 8. pii: 477216. doi: 10.1182/blood.2020010405.
    PubMed     Abstract available

  162. PROSSER AL, Li W
    Salmon-colored granules in the leukemic blasts of B-lymphoblastic leukemia with iAMP21.
    Blood. 2021;138:1282.

    September 2021
  163. SIERRA J, Nomdedeu JF
    CEBPA bZip mutations: just a single shot.
    Blood. 2021;138:1091-1092.

  164. XU D, Naresh KN
    Leukemic presentation of a highly aggressive ALK-negative anaplastic large cell lymphoma.
    Blood. 2021;138:1198.

  165. STEPHENS DM, Byrd JC
    Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies.
    Blood. 2021;138:1099-1109.
    PubMed     Abstract available

  166. TARLOCK K, Lamble AJ, Wang YC, Gerbing RB, et al
    CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group.
    Blood. 2021;138:1137-1147.
    PubMed     Abstract available

  167. ALEJO-VALLE O, Weigert K, Bhayadia R, Ng M, et al
    The megakaryocytic transcription factor ARID3A suppresses leukemia pathogenesis.
    Blood. 2021 Sep 27. pii: 477055. doi: 10.1182/blood.2021012231.
    PubMed     Abstract available

    Cell cycle control in Richter transformation.
    Blood. 2021;138:1005-1007.

  169. HAN C, Ntziachristos P
    T-ALL and the talented Mr IL7Ralpha.
    Blood. 2021;138:1003-1004.

  170. YU X, Munoz-Sagredo L, Streule K, Muschong P, et al
    CD44 loss of function sensitizes AML cells to the BCL-2 inhibitor venetoclax by decreasing CXCL12-driven survival cues.
    Blood. 2021;138:1067-1080.
    PubMed     Abstract available

  171. CHAKRABORTY S, Martines C, Porro F, Fortunati I, et al
    B-cell receptor signaling and genetic lesions in TP53 and CDKN2A/CDKN2B cooperate in Richter transformation.
    Blood. 2021;138:1053-1066.
    PubMed     Abstract available

  172. DEANGELO DJ, Jonas BA, Liesveld JL, Bixby DL, et al
    Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia.
    Blood. 2021 Sep 20. pii: 476977. doi: 10.1182/blood.2021010721.
    PubMed     Abstract available

  173. BERMAN E
    How I Treat Chronic Phase Chronic Myelogenous Leukemia.
    Blood. 2021 Sep 16. pii: 476939. doi: 10.1182/blood.2021011722.
    PubMed     Abstract available

  174. PAIETTA E, Roberts KG, Wang V, Gu Z, et al
    Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL.
    Blood. 2021;138:948-958.
    PubMed     Abstract available

  175. AMAYA M, Inguva A, Pei S, Jones CL, et al
    The STAT3-MYC Axis Promotes Survival of Leukemia Stem Cells by Regulating SLC1A5 and Oxidative Phosphorylation.
    Blood. 2021 Sep 15. pii: 476917. doi: 10.1182/blood.2021013201.
    PubMed     Abstract available

  176. SAMARAWEERA SE, Wang PP, Li KL, Casolari DA, et al
    Childhood Acute Myeloid Leukemia shows a high level of germline predisposition.
    Blood. 2021 Sep 14. pii: 476894. doi: 10.1182/blood.2021012666.

  177. ROSSOFF J, Baggott C, Prabhu S, Pacenta HL, et al
    Out of Specification Tisagenlecleucel Does Not Compromise Safety or Efficacy in Pediatric Acute Lymphoblastic Leukemia.
    Blood. 2021 Sep 9. pii: 476839. doi: 10.1182/blood.2021012392.

  178. MA S, Seymour JF, Brander DM, Kipps TJ, et al
    Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy.
    Blood. 2021;138:836-846.
    PubMed     Abstract available

  179. DAVIS AG, Johnson DT, Zheng D, Wang R, et al
    Alternative polyadenylation dysregulation contributes to the differentiation block of acute myeloid leukemia.
    Blood. 2021 Sep 5. pii: 476791. doi: 10.1182/blood.2020005693.
    PubMed     Abstract available

    BCL11B, the Cerberus of human leukemia.
    Blood. 2021;138:741-743.

  181. SILVA O, Kurzer J
    Nonleukemic T/B mixed phenotype acute leukemia with PHF6 and NOTCH1 mutations.
    Blood. 2021;138:818.

  182. IMGRUET MK, Lutze J, An N, Hu B, et al
    Loss of a 7q gene, CUX1, disrupts epigenetically driven DNA repair and drives therapy-related myeloid neoplasms.
    Blood. 2021;138:790-805.
    PubMed     Abstract available

    August 2021
  183. HERLING M, Wahnschaffe L
    Altered epigenetics at the center of NK-LGL leukemia.
    Blood. 2021;138:589-591.

  184. WHEAT JC, Steidl U
    Gene expression at a single-molecule level: implications for myelodysplastic syndromes and acute myeloid leukemia.
    Blood. 2021;138:625-636.
    PubMed     Abstract available

  185. JANN JC, Tothova Z
    Cohesin mutations in myeloid malignancies.
    Blood. 2021;138:649-661.
    PubMed     Abstract available

  186. QING Y, Su R, Chen J
    RNA modifications in hematopoietic malignancies: a new research frontier.
    Blood. 2021;138:637-648.
    PubMed     Abstract available

  187. MESSLING JE, Agger K, Andersen KL, Kromer K, et al
    Targeting RIOK2 ATPase activity leads to decreased protein synthesis and cell death in acute myeloid leukemia.
    Blood. 2021 Aug 25. pii: 476529. doi: 10.1182/blood.2021012629.
    PubMed     Abstract available

  188. ASTOLFI A, Masetti R, Indio V, Bertuccio SN, et al
    Torque Teno Mini Virus as a cause of childhood acute promyelocytic leukemia lacking PML/RARA fusion.
    Blood. 2021 Aug 25. pii: 476664. doi: 10.1182/blood.2021011677.

  189. ZANETTI C, Kumar R, Ender J, Godavarthy PS, et al
    The age of the bone marrow microenvironment influences B-cell acute lymphoblastic leukemia progression via CXCR5-CXCL13.
    Blood. 2021 Aug 23. pii: 476652. doi: 10.1182/blood.2021011557.
    PubMed     Abstract available

  190. DERECKA M
    AML onco-niche: villain or ally?
    Blood. 2021;138:504-506.

  191. BURGER JA
    CLL cells are moved by the MARCKS brothers.
    Blood. 2021;138:503-504.

    A slow-go prognosis for older patients with newly diagnosed AML.
    Blood. 2021;138:501-502.

  193. Genetic decision model for fit older AML patients.
    Blood. 2021;138:585.

  194. ITZYKSON R, Fournier E, Berthon C, Rollig C, et al
    Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy.
    Blood. 2021;138:507-519.
    PubMed     Abstract available

  195. WUDHIKARN K, Flynn JR, Riviere I, Gonen M, et al
    Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy.
    Blood. 2021;138:531-543.
    PubMed     Abstract available

  196. BECKMANN L, Berg V, Dickhut C, Sun C, et al
    MARCKS affects cell motility and response to BTK inhibitors in CLL.
    Blood. 2021;138:544-556.
    PubMed     Abstract available

  197. CORTES J, Apperley JF, Lomaia E, Moiraghi B, et al
    Ponatinib Dose-Ranging Study in Chronic-Phase Chronic Myeloid Leukemia: A Randomized, Open-Label Phase 2 Clinical Trial.
    Blood. 2021 Aug 18. pii: 476603. doi: 10.1182/blood.2021012082.
    PubMed     Abstract available

  198. GUO D, Zhao Y, Wang N, You N, et al
    GADD45g acts as a novel tumor suppressor, and its activation suggests new combination regimens for the treatment of AML.
    Blood. 2021;138:464-479.
    PubMed     Abstract available

  199. ALVES DA SILVA PH, Xing S, Kotini AG, Papapetrou EP, et al
    MICA/B antibody induces macrophage-mediated immunity against acute myeloid leukemia.
    Blood. 2021 Aug 6. pii: 476528. doi: 10.1182/blood.2021011619.
    PubMed     Abstract available

  200. YANG S, Zhu XN, Zhang HL, Yang Q, et al
    ANP32B-mediated repression of p53 contributes to maintenance of normal and CML stem cells.
    Blood. 2021 Aug 6. pii: 476526. doi: 10.1182/blood.2020010400.
    PubMed     Abstract available

  201. SORROR ML, Storer BE, Fathi AT, Brunner A, et al
    Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia.
    Blood. 2021;138:387-400.
    PubMed     Abstract available

    July 2021
  202. HALSEY C, Escherich G
    A "Goldilocks" approach to CNS leukemia is needed.
    Blood. 2021;138:288-289.

  203. SAUER T, Parikh K, Sharma S, Omer B, et al
    CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity.
    Blood. 2021;138:318-330.
    PubMed     Abstract available

  204. TAUBE F, Georgi JA, Kramer M, Stasik S, et al
    CEBPA Mutations in 4708 Patients with Acute Myeloid Leukemia - Differential Impact of bZIP and TAD Mutations on Outcome.
    Blood. 2021 Jul 28. pii: 476465. doi: 10.1182/blood.2020009680.
    PubMed     Abstract available

  205. KOLLMANN S, Grausenburger R, Klampfl T, Prchal-Murphy M, et al
    A STAT5B-CD9 axis determines self-renewal in hematopoietic and leukemic stem cells.
    Blood. 2021 Jul 28. pii: 476469. doi: 10.1182/blood.2021010980.
    PubMed     Abstract available

  206. PUZZOLO MC, Radice G, Peragine N, de Propris MS, et al
    Host immune system modulation in Ph+ acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab.
    Blood. 2021 Jul 23. pii: 476452. doi: 10.1182/blood.2021011822.

  207. GOOPTU M, Romee R, St Martin A, Arora M, et al
    HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis.
    Blood. 2021;138:273-282.
    PubMed     Abstract available

  208. LEE JB, Khan DH, Hurren R, Xu M, et al
    Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production.
    Blood. 2021;138:234-245.
    PubMed     Abstract available

  209. MORANDE PE, Yan XJ, Sepulveda J, Seija N, et al
    AID overexpression leads to aggressive murine CLL and nonimmunoglobulin mutations that mirror human neoplasms.
    Blood. 2021;138:246-258.
    PubMed     Abstract available

  210. JETANI H, Navarro-Bailon A, Maucher M, Frenz S, et al
    Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia (AML).
    Blood. 2021 Jul 21. pii: 476427. doi: 10.1182/blood.2020009192.
    PubMed     Abstract available

  211. BUTLER M, van Ingen Schenau DS, Yu J, Jenni S, et al
    BTK inhibition sensitizes Acute Lymphoblastic Leukemia to asparaginase by suppressing the Amino Acid Response pathway.
    Blood. 2021 Jul 19. pii: 476421. doi: 10.1182/blood.2021011787.
    PubMed     Abstract available

  212. KUTSCH N
    CLL-IPI: valid in the era of oral inhibitors?
    Blood. 2021;138:106-107.

  213. PARIKH SA, Rabe KG, Kay NE, Call TG, et al
    The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL.
    Blood. 2021;138:149-159.
    PubMed     Abstract available

  214. MULET-LAZARO R, van Herk S, Erpelinck C, Bindels E, et al
    Allele-specific expression of GATA2 due to epigenetic dysregulation in CEBPA double-mutant AML.
    Blood. 2021;138:160-177.
    PubMed     Abstract available

  215. ZHENG W, Wei J, Zebley CC, Jones LL, et al
    Regnase-1 suppresses TCF-1+ precursor exhausted T-cell formation to limit CAR-T-cell responses against ALL.
    Blood. 2021;138:122-135.
    PubMed     Abstract available

  216. KRANC KR
    The essential reading list for AML: the m6A transcripts.
    Blood. 2021;138:6-7.

  217. LINLEY AJ, Slupsky JR
    Poor prognosis is ZAP70'ed into focus in CLL.
    Blood. 2021;137:3586-3587.

    June 2021
  218. MEIER-ABT F, Lu J, Cannizzaro E, Pohly MF, et al
    The Protein Landscape of Chronic Lymphocytic Leukemia (CLL).
    Blood. 2021 Jun 29. pii: 476272. doi: 10.1182/blood.2020009741.
    PubMed     Abstract available

  219. TABE Y, Konopleva M
    Break the lifeline of AML cells.
    Blood. 2021;137:3465-3467.

  220. MORENO C
    Autoimmune cytopenia and CLL ride together.
    Blood. 2021;137:3464-3465.

  221. VITALE C, Salvetti C, Griggio V, Porrazzo M, et al
    Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs.
    Blood. 2021;137:3507-3517.
    PubMed     Abstract available

  222. MULLER MR
    A new option for Richter syndrome.
    Blood. 2021;137:3318-3319.

  223. SMOLEJ L
    On the road to optimized BTK inhibition in CLL.
    Blood. 2021;137:3313-3314.

  224. LOKE J, Cockerill PN
    Unravelling the apoptotic machinery in CMML.
    Blood. 2021;137:3321-3322.

  225. IANNELLO A, Vitale N, Coma S, Arruga F, et al
    Synergistic efficacy of the dual PI3K-delta/gamma inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models.
    Blood. 2021;137:3378-3389.
    PubMed     Abstract available

  226. SEVIN M, Debeurme F, Laplane L, Badel S, et al
    Cytokine-like protein 1-induced survival of monocytes suggests a combined strategy targeting MCL1 and MAPK in CMML.
    Blood. 2021;137:3390-3402.
    PubMed     Abstract available

  227. VAISITTI T, Arruga F, Vitale N, Lee TT, et al
    ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models.
    Blood. 2021;137:3365-3377.
    PubMed     Abstract available

  228. KATERNDAHL CDS, Rogers ORS, Day RB, Cai MA, et al
    Tumor suppressor function of Gata2 in Acute Promyelocytic Leukemia.
    Blood. 2021 Jun 14. pii: 476182. doi: 10.1182/blood.2021011758.
    PubMed     Abstract available

  229. RUBNITZ JE, Kaspers GJL
    How I treat pediatric acute myeloid leukemia.
    Blood. 2021 Jun 11. pii: 476140. doi: 10.1182/blood.2021011694.
    PubMed     Abstract available

  230. LV K, Ren JG, Han X, Gui J, et al
    Depalmitoylation Rewires FLT3-ITD Signaling and Exacerbates Leukemia Progression.
    Blood. 2021 Jun 10. pii: 476131. doi: 10.1182/blood.2021011582.
    PubMed     Abstract available

  231. MALOUF C, Antunes ETB, O'Dwyer M, Jakobczyk H, et al
    MiR-130b and miR-128a are essential lineage-specific co-drivers of t(4;11) MLL-AF4 acute leukemia.
    Blood. 2021 Jun 10. pii: 476129. doi: 10.1182/blood.2020006610.
    PubMed     Abstract available

  232. CHANG Y, Min J, Jarusiewicz J, Actis M, et al
    Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia.
    Blood. 2021 Jun 10. pii: 476126. doi: 10.1182/blood.2020006846.
    PubMed     Abstract available

    Vaccination against COVID-19: a challenge in CLL.
    Blood. 2021;137:3153-3154.

    Checkpoint-blocked T cells checkmate AML.
    Blood. 2021;137:3155-3156.

  235. HERLING M, Braun T
    Tracing the roots of CLPD-NK by TET2 and STAT3.
    Blood. 2021;137:3156-3158.

  236. YUAN Y, Boyle S
    All that glitters is not gold: pseudoplatelets associated with tumour lysis in high-blast-count AML.
    Blood. 2021;137:3310.

  237. PENTER L, Zhang Y, Savell A, Huang T, et al
    Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation.
    Blood. 2021;137:3212-3217.
    PubMed     Abstract available

  238. FOSTER MC, Savoldo B, Lau W, Rubinos C, et al
    Utility of a safety switch to abrogate CD19.CAR T-cell-associated neurotoxicity.
    Blood. 2021;137:3306-3309.

  239. BOLDRIN E, Gaffo E, Niedermayer A, Boer JM, et al
    MicroRNA-497/195 is tumor-suppressive and cooperates with CDKN2A/B in pediatric acute lymphoblastic leukemia.
    Blood. 2021 Jun 7. pii: 476100. doi: 10.1182/blood.2020007591.
    PubMed     Abstract available

  240. JONES RJ, DeBaun MR
    Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both or neither.
    Blood. 2021 Jun 3. pii: 476065. doi: 10.1182/blood.2021011488.
    PubMed     Abstract available

  241. TANAKA T, Morita K, Wang F, Loghavi S, et al
    Clonal Dynamics and clinical implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML).
    Blood. 2021 Jun 3. pii: 476064. doi: 10.1182/blood.2020010483.
    PubMed     Abstract available

    Revisiting TLR9 as a target for CLL therapy.
    Blood. 2021;137:3006-3008.

  243. WERMKE M, Kraus S, Ehninger A, Bargou RC, et al
    Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML.
    Blood. 2021;137:3145-3148.

  244. SOMASUNDARAM R, Jensen CT, Tingvall-Gustafsson J, Ahsberg J, et al
    EBF1 and PAX5 control pro-B cell expansion via opposing regulation of the Myc gene.
    Blood. 2021;137:3037-3049.
    PubMed     Abstract available

  245. DUAULT C, Kumar A, Taghi Khani A, Lee SJ, et al
    Activated Natural Killer Cells Predict Poor Clinical Prognosis in High-risk B- and T- cell Acute Lymphoblastic Leukemia.
    Blood. 2021 Jun 2. pii: 476053. doi: 10.1182/blood.2020009871.
    PubMed     Abstract available

  246. AWADA H, Durmaz A, Gurnari C, Kishtagari A, et al
    Machine Learning Integrates Genomic Signatures for Subclassification Beyond Primary and Secondary Acute Myeloid Leukemia.
    Blood. 2021 Jun 1. pii: 476049. doi: 10.1182/blood.2020010603.
    PubMed     Abstract available

  247. STEVENSON FK, Forconi F, Kipps TJ
    Exploring the Pathways to Chronic Lymphocytic Leukemia.
    Blood. 2021 Jun 1. pii: 476048. doi: 10.1182/blood.2020010029.
    PubMed     Abstract available

  248. THOMS JAI, Truong P, Subramanian S, Knezevic K, et al
    Disruption of a GATA2, TAL1, ERG regulatory circuit promotes erythroid transition in healthy and leukemic stem cells.
    Blood. 2021 Jun 1. pii: 476046. doi: 10.1182/blood.2020009707.
    PubMed     Abstract available

    May 2021
  249. GHIA P, Stamatopoulos K
    In CLL, epigenetics also points to the BCR.
    Blood. 2021;137:2863-2865.

  250. MASS J, Park DC
    Posttransplant T lymphoblastic lymphoma mimicking Burkitt lymphoma.
    Blood. 2021;137:3002.

  251. COORENS THH, Collord G, Lu W, Mitchell E, et al
    Clonal hematopoiesis and therapy-related myeloid neoplasms following neuroblastoma treatment.
    Blood. 2021;137:2992-2997.

  252. WANG D, Wang J, Hu G, Wang W, et al
    A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma.
    Blood. 2021;137:2890-2901.
    PubMed     Abstract available

  253. FOWLER N
    Kinase inhibitors in CLL: drawing the roadmap.
    Blood. 2021;137:2717-2719.

  254. GANSER A
    What can Heraclitus tell us about AML?
    Blood. 2021;137:2719-2720.

  255. LIU H
    Basophilic myeloblasts: a clue for CML blast phase.
    Blood. 2021;137:2852.

  256. MUSANI R, Chang H
    Coexistence of BCR-ABL1 and RUNX1-RUNX1T1 in a de novo AML.
    Blood. 2021;137:2853.

  257. DUCHMANN M, Micol JB, Duployez N, Raffoux E, et al
    Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study.
    Blood. 2021;137:2827-2837.
    PubMed     Abstract available

  258. THIJSSEN R, Diepstraten ST, Moujalled D, Chew E, et al
    Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias.
    Blood. 2021;137:2721-2735.
    PubMed     Abstract available

  259. MATO AR, Ghosh N, Schuster SJ, Lamanna N, et al
    Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kdelta inhibitor therapy.
    Blood. 2021;137:2817-2826.
    PubMed     Abstract available

  260. BORELLA G, Da Ros A, Borile G, Porcu E, et al
    Targeting mesenchymal stromal cells plasticity to reroute acute myeloid leukemia course.
    Blood. 2021 May 19. pii: 475978. doi: 10.1182/blood.2020009845.
    PubMed     Abstract available

  261. VAN DER KOUWE E, Heller G, Czibere A, Pulikkan JA, et al
    Core binding factor leukemia hijacks T-cell prone PU.1 antisense promoter.
    Blood. 2021 May 19. pii: 475975. doi: 10.1182/blood.2020008971.
    PubMed     Abstract available

  262. BISHOP DC, Clancy LE, Simms R, Burgess J, et al
    Development of CAR T-cell lymphoma in two of ten patients effectively treated with piggyBac modified CD19 CAR T-cells.
    Blood. 2021 May 19. pii: 475980. doi: 10.1182/blood.2021010813.
    PubMed     Abstract available

  263. ESCRIBANO SERRAT S, Calo Perez A
    Pure erythroid leukemia.
    Blood. 2021;137:2709.

  264. TAKEDA MR, Gurbuxani S
    bcr3 PML-RARA: short fusion, small blasts!
    Blood. 2021;137:2708.

  265. SURAPALLY S, Tenen DG, Pulikkan JA
    Emerging therapies for inv(16) AML.
    Blood. 2021;137:2579-2584.
    PubMed     Abstract available

  266. KIRCHHOFF H, Karsli U, Schoenherr C, Battmer K, et al
    Venetoclax and dexamethasone synergize with inotuzumab ozogamicin-induced DNA damage signaling in B-lineage ALL.
    Blood. 2021;137:2657-2661.
    PubMed     Abstract available

  267. MICKLETHWAITE KP, Gowrishankar K, Gloss BS, Li Z, et al
    Investigation of product derived lymphoma following infusion of piggyBac modified CD19 chimeric antigen receptor T-cells.
    Blood. 2021 May 11. pii: 475942. doi: 10.1182/blood.2021010858.
    PubMed     Abstract available

  268. SILVA AP, Almeida ARM, Cachucho A, Neto JL, et al
    Overexpression of wild type IL-7Ralpha promotes T-cell acute lymphoblastic leukemia/lymphoma.
    Blood. 2021 May 10. pii: 475938. doi: 10.1182/blood.2019000553.
    PubMed     Abstract available

  269. WIMMER J, Hurstel R
    Systemic mastocytosis with an associated t(8;21)(q22;q22) acute myeloid leukemia.
    Blood. 2021;137:2564.

  270. PADI SKR, Kraft AS
    "Root"ing for successful T-ALL treatment.
    Blood. 2021;137:2422-2423.

  271. GEOFFROY MC, Esnault C, de The H
    Retinoids in hematology: a timely revival?
    Blood. 2021;137:2429-2437.
    PubMed     Abstract available

  272. ANAND P, Guillaumet-Adkins A, Dimitrova V, Yun H, et al
    Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL.
    Blood. 2021;137:2463-2480.
    PubMed     Abstract available

    April 2021
  273. ANDRIEU GP, Asnafi V
    Integrated omics approaches to predict T-LBL relapse risk.
    Blood. 2021;137:2280-2282.

  274. TERRE C, Raggueneau V
    Double insertion in normal karyotype CML.
    Blood. 2021;137:2418.

  275. SORROR ML, Storer BE, Fathi AT, Brunner AM, et al
    Multi-Site 11-Year Experience of Less-Intensive versus Intensive Therapies in Acute Myeloid Leukemia.
    Blood. 2021 Apr 28. pii: 475848. doi: 10.1182/blood.2020008812.
    PubMed     Abstract available

  276. CHATZIDIMITRIOU C, Vassilakopoulos TP
    Rapidly deteriorating B-CLL at presentation: clonally related Burkitt leukemia as an atypical Richter transformation?
    Blood. 2021;137:2272.

    IL-9 in CLL: sensing home and settling down!
    Blood. 2021;137:2130-2131.

  278. SOARES F, Chen B, Lee JB, Ahmed M, et al
    CRISPR screen identifies genes that sensitize AML cells to double-negative T-cell therapy.
    Blood. 2021;137:2171-2181.
    PubMed     Abstract available

  279. DA SILVA-DIZ V, Cao B, Lancho O, Chiles E, et al
    A novel and highly effective mitochondrial uncoupling drug in T-cell leukemia.
    Blood. 2021 Apr 19. pii: 475782. doi: 10.1182/blood.2020008955.
    PubMed     Abstract available

  280. MITTELMAN SD, Kim J, Raca G, Li G, et al
    Increased prevalence of CRLF2 rearrangements in obesity-associated acute lymphoblastic leukemia.
    Blood. 2021 Apr 19. pii: 475790. doi: 10.1182/blood.2021011106.

  281. LEW TE, Tam CS, Seymour JF
    How I treat chronic lymphocytic leukemia after venetoclax.
    Blood. 2021 Apr 19. pii: 475780. doi: 10.1182/blood.2020008502.
    PubMed     Abstract available

  282. DI GIACOMO D, La Starza R, Gorello P, Pellanera F, et al
    14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T and myeloid immature acute leukemia.
    Blood. 2021 Apr 19. pii: 475778. doi: 10.1182/blood.2020010510.
    PubMed     Abstract available

  283. HERISHANU Y, Avivi I, Aharon A, Shefer G, et al
    Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia.
    Blood. 2021 Apr 16. pii: 475742. doi: 10.1182/blood.2021011568.
    PubMed     Abstract available

  284. AMES E, Silva O
    Polytypic T-cell prolymphocytic leukemia.
    Blood. 2021;137:2125.

  285. SANDBERG Y, Weerkamp F
    Charcot-Leyden crystals in chronic eosinophilic leukemia.
    Blood. 2021;137:1985.

  286. SEFTEL MD
    Has MRD graduated from its adolescence in ALL?
    Blood. 2021;137:1846-1847.

  287. KENNEDY GA, Tey SK, Buizen L, Varelias A, et al
    A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin/methotrexate GVHD prophylaxis.
    Blood. 2021;137:1970-1979.
    PubMed     Abstract available

  288. GEMENETZI K, Psomopoulos F, Carriles AA, Gounari M, et al
    Higher-order immunoglobulin repertoire restrictions in CLL: the illustrative case of stereotyped subsets 2 and 169.
    Blood. 2021;137:1895-1904.
    PubMed     Abstract available

  289. SHAH BD, Bishop MR, Oluwole OO, Logan AC, et al
    KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results.
    Blood. 2021 Apr 7. pii: 475697. doi: 10.1182/blood.2020009098.
    PubMed     Abstract available

  290. WEI AH, Daver N
    Taking aim at IDH in fitter patients with AML.
    Blood. 2021;137:1706-1707.

  291. SCHWAB C, Roberts K, Boer JM, Gohring G, et al
    SSBP2-CSF1R is a recurrent fusion in B-lineage acute lymphoblastic leukemia with diverse genetic presentation and variable outcome.
    Blood. 2021;137:1835-1838.

  292. STEIN EM, DiNardo CD, Fathi AT, Mims AS, et al
    Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
    Blood. 2021;137:1792-1803.
    PubMed     Abstract available

    March 2021
  293. BYRD JC, Woyach JA, Furman RR, Martin P, et al
    Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia.
    Blood. 2021 Mar 30. pii: 475651. doi: 10.1182/blood.2020009617.
    PubMed     Abstract available

  294. NIU X, Rothe K, Chen M, Grasedieck S, et al
    Targeting AXL Kinase Sensitizes Leukemic Stem and Progenitor Cells to Venetoclax Treatment in Acute Myeloid Leukemia.
    Blood. 2021 Mar 30. pii: 475648. doi: 10.1182/blood.2020007651.
    PubMed     Abstract available

  295. OLSON TL, Cheon H, Xing JC, Olson KC, et al
    Frequent Somatic TET2 Mutations in Chronic NK-LGL Leukemia with Distinct Patterns of Cytopenias.
    Blood. 2021 Mar 30. pii: 475646. doi: 10.1182/blood.2020005831.
    PubMed     Abstract available

  296. SEDA V, Vojackova E, Ondrisova L, Kostalova L, et al
    FoxO1-GAB1 Axis Regulates Homing Capacity and Tonic AKT Activity in Chronic Lymphocytic Leukemia.
    Blood. 2021 Mar 30. pii: 475649. doi: 10.1182/blood.2020008101.
    PubMed     Abstract available

  297. ZHANG JP, Cheng T
    Modeling acute erythroid leukemia via CRISPR.
    Blood. 2021;137:1565-1567.

  298. CHANG H, Eladl E
    Multiple Auer rods in a mixed-phenotype acute leukemia.
    Blood. 2021;137:1702.

  299. JABBOUR E, Kantarjian H
    A new era in the treatment of acute lymphoblastic leukemia.
    Blood. 2021;137:1563-1564.

  300. IACOBUCCI I, Qu C, Varotto E, Janke LJ, et al
    Modeling and targeting of erythroleukemia by hematopoietic genome editing.
    Blood. 2021;137:1628-1640.
    PubMed     Abstract available

  301. SIMONIN M, Lhermitte L, Dourthe ME, Lengline E, et al
    IKZF1 alterations predict poor prognosis in adult and pediatric T-ALL.
    Blood. 2021;137:1690-1694.

  302. FENG M, Xie X, Han G, Zhang T, et al
    YBX1 is required for maintaining myeloid leukemia cell survival by regulating BCL2 stability in an m6A-dependent manner.
    Blood. 2021 Mar 24. pii: 475592. doi: 10.1182/blood.2020009676.
    PubMed     Abstract available

  303. ROGERS KA, Andritsos LA, Wei L, McLaughlin E, et al
    Phase 2 Study of Ibrutinib in Classic and Variant Hairy Cell Leukemia.
    Blood. 2021 Mar 22. pii: 475585. doi: 10.1182/blood.2020009688.
    PubMed     Abstract available

  304. HOSOKAWA K, Mizumaki H, Yoroidaka T, Maruyama H, et al
    HLA class I allele-lacking leukocytes predict rare clonal evolution to MDS/AML in patients with acquired aplastic anemia.
    Blood. 2021 Mar 22. pii: 475586. doi: 10.1182/blood.2020010586.

  305. RASLAN O, Hsia CC
    Cabot rings in acute myeloid leukemia.
    Blood. 2021;137:1560.

  306. KOGAN SC
    PML-RARalpha: changing myeloid networks.
    Blood. 2021;137:1439-1440.

  307. TCHENG M, Roma A, Ahmed N, Smith RW, et al
    Very long chain fatty acid metabolism is required in acute myeloid leukemia.
    Blood. 2021 Mar 15. pii: 475526. doi: 10.1182/blood.2020008551.
    PubMed     Abstract available

  308. SAUER T, Parikh K, Sharma S, Omer B, et al
    CD70-specific CAR T-cells have potent activity against Acute Myeloid Leukemia (AML) without HSC toxicity.
    Blood. 2021 Mar 15. pii: 475523. doi: 10.1182/blood.2020008221.
    PubMed     Abstract available

  309. ERNST MPT, Kavelaars FG, Lowenberg B, Valk PJM, et al
    RUNX1 germline variants in RUNX1-mutant AML: how frequent?
    Blood. 2021;137:1428-1431.

  310. AGATHANGELIDIS A, Chatzidimitriou A, Gemenetzi K, Giudicelli V, et al
    Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL.
    Blood. 2021;137:1365-1376.
    PubMed     Abstract available

  311. MURALI I, Kasar S, Naeem A, Tyekucheva S, et al
    Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia (cll).
    Blood. 2021 Mar 8. pii: 475459. doi: 10.1182/blood.2020006765.
    PubMed     Abstract available

  312. TANG J, Yu J, Cai J, Zhang L, et al
    Prognostic Factors for CNS Control in Children with Acute Lymphoblastic Leukemia Treated Without Cranial Irradiation.
    Blood. 2021 Mar 8. pii: 475463. doi: 10.1182/blood.2020010438.
    PubMed     Abstract available

  313. NAZHA A
    Should I rock the boat? When to stop TKIs in CML.
    Blood. 2021;137:1136-1137.

    February 2021
    CAR-T treatment of pediatric AML: a long and winding road.
    Blood. 2021;137:1004-1006.

  315. MICHALLET AS, Letestu R, Le Garff-Tavernier M, Aanei C, et al
    A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial.
    Blood. 2021;137:1019-1023.
    PubMed     Abstract available

  316. WILLIER S, Rothamel P, Hastreiter M, Wilhelm J, et al
    CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy.
    Blood. 2021;137:1037-1049.
    PubMed     Abstract available

  317. HOFF FW, van Dijk AD, Qiu Y, Ruvolo PP, et al
    Heat shock factor 1 (HSF1-pSer326) predicts response to bortezomib-containing chemotherapy in pediatric AML: a COG report.
    Blood. 2021;137:1050-1060.
    PubMed     Abstract available

  318. CHEN J, Sathiaseelan V, Moore AD, Tan S, et al
    ZAP-70 constitutively regulates gene expression and protein synthesis in chronic lymphocytic leukemia.
    Blood. 2021 Feb 22. pii: 475287. doi: 10.1182/blood.2020009960.
    PubMed     Abstract available

  319. Pediatric disease risk index for acute leukemia.
    Blood. 2021;137:1001.

  320. QAYED M, Ahn KW, Kitko CL, Johnson MH, et al
    A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation.
    Blood. 2021;137:983-993.
    PubMed     Abstract available

  321. SERA Y, Nakata Y, Ueda T, Yamasaki N, et al
    UTX maintains the functional integrity of the murine hematopoietic system by globally regulating aging-associated genes.
    Blood. 2021;137:908-922.
    PubMed     Abstract available

  322. LEONARD JT, Kosaka Y, Malla P, LaTocha D, et al
    Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL.
    Blood. 2021;137:939-944.
    PubMed     Abstract available

  323. SCHMALBROCK LK, Dolnik A, Cocciardi S, Strang E, et al
    Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin.
    Blood. 2021 Feb 17. pii: 475246. doi: 10.1182/blood.2020007626.
    PubMed     Abstract available

  324. HERBAUX C, Kornauth C, Poulain S, Chong SJF, et al
    BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia.
    Blood. 2021 Feb 17. pii: 475244. doi: 10.1182/blood.2020007303.
    PubMed     Abstract available

  325. GILL S
    DARTs point the way forward in AML.
    Blood. 2021;137:720-721.

  326. NG AP
    Unraveling a T-ALL Tapestri.
    Blood. 2021;137:726-727.

  327. HERGOTT CB, Pozdnyakova O
    Beware the "other AML": hepatic angiomyolipoma with extensive extramedullary hematopoiesis.
    Blood. 2021;137:860.

  328. RAASTAD K, Huang Q
    Burkitt leukemia with immature B-cell phenotype mimicking acute lymphoblastic leukemia.
    Blood. 2021;137:718.

  329. GRANT S
    Targeting cereblon in AML.
    Blood. 2021;137:584-586.

  330. BROWN JR
    AKT: a key to RT?
    Blood. 2021;137:582-584.

  331. KOHLHAAS V, Blakemore SJ, Al-Maarri M, Nickel N, et al
    Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1.
    Blood. 2021;137:646-660.
    PubMed     Abstract available

  332. FALINI B, Brunetti L, Martelli MP
    How I diagnose and treat NPM1-mutated AML.
    Blood. 2021;137:589-599.
    PubMed     Abstract available

    January 2021
  333. GODWIN CD, Zhou Y, Othus M, Asmuth MM, et al
    Acute myeloid leukemia measurable residual disease detection by flow cytometry in peripheral blood vs bone marrow.
    Blood. 2021;137:569-572.

  334. RODERICK JE, Gallagher KM, Murphy LC, O'Connor KW, et al
    Prostaglandin E2 stimulates cAMP signaling and resensitizes human leukemia cells to glucocorticoid-induced cell death.
    Blood. 2021;137:500-512.
    PubMed     Abstract available

  335. SHOUVAL R, Soiffer RJ
    Primum non nocere: allo-HSCT for AML in CR1.
    Blood. 2021;137:438-439.

  336. COHEN AUBART F, Roos-Weil D, Armand M, Marceau-Renaut A, et al
    High frequency of clonal hematopoiesis in Erdheim-Chester disease.
    Blood. 2021;137:485-492.
    PubMed     Abstract available

  337. ZHAO Y, Aldoss I, Qu C, Crawford JC, et al
    Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL.
    Blood. 2021;137:471-484.
    PubMed     Abstract available

  338. SONG Q, Wang X, Wu X, Qin H, et al
    Tolerogenic anti-IL-2 mAb prevents graft-versus-host disease while preserving strong graft-versus-leukemia activity.
    Blood. 2021 Jan 27. pii: 475053. doi: 10.1182/blood.2020006345.
    PubMed     Abstract available

  339. RIO-MACHIN A, Fitzgibbon J
    Germline ETV6 variants: not ALL created equally.
    Blood. 2021;137:288-289.

  340. GAUTHIER J, Bezerra ED, Hirayama AV, Fiorenza S, et al
    Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies.
    Blood. 2021;137:323-335.
    PubMed     Abstract available

  341. WEN Z, Yun G, Hebert A, Kong G, et al
    NrasQ61R/+ and Kras-/- cooperate to downregulate Rasgrp1 and promote lympho-myeloid leukemia in early T-cell precursors.
    Blood. 2021 Jan 19. pii: 475000. doi: 10.1182/blood.2020009082.
    PubMed     Abstract available

  342. SHADMAN M, Ujjani C
    Vaccinations in CLL: implications for COVID-19.
    Blood. 2021;137:144-146.

  343. MERTENS D, Kronke J
    Triggering T-cell activity in CLL.
    Blood. 2021;137:150-151.

  344. MASS J, Alobeid B
    Composite mantle cell lymphoma and small lymphocytic lymphoma in a lymph node.
    Blood. 2021;137:282.

  345. AL MOOSAWI M, Vercauteren S
    Cerebrospinal fluid with unusual natural killer cell population.
    Blood. 2021;137:281.

  346. IOANNOU N, Hagner PR, Stokes M, Gandhi AK, et al
    Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy.
    Blood. 2021;137:216-231.
    PubMed     Abstract available

  347. SALIB C, Hussein S
    A case of hairy cell leukemia with markedly hypocellular marrow mimicking aplastic anemia.
    Blood. 2021;137:142.

  348. SIDHOM I, Shaaban K, Youssef SH, Ali N, et al
    Reduced-intensity therapy for pediatric lymphoblastic leukemia: impact of residual disease early in remission induction.
    Blood. 2021;137:20-28.
    PubMed     Abstract available

  349. KENNEDY E, Coulter EM, Halliwell E, Profitos-Peleja N, et al
    TLR9 expression in Chronic Lymphocytic Leukemia identifies a pro-migratory subpopulation and novel therapeutic target.
    Blood. 2021 Jan 7. pii: 474915. doi: 10.1182/blood.2020005964.
    PubMed     Abstract available

  350. CORRE J
    Undetectable MRD can change the deal.
    Blood. 2021;137:5-6.

  351. KEESHAN K
    Superenhancing AML with Trib1.
    Blood. 2021;137:8-9.

    December 2020
  352. MATTERN S, Nann D
    Small lymphocytic leukemia with herpes simplex virus infection simulating metastatic cancer.
    Blood. 2020;136:3087.

  353. KAPP-SCHWOERER S, Weber D, Corbacioglu A, Gaidzik VI, et al
    Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial.
    Blood. 2020;136:3041-3050.
    PubMed     Abstract available

  354. FURSTENAU M, Fink AM, Schilhabel A, Weiss J, et al
    B-cell Acute Lymphoblastic Leukemia in Patients with Chronic Lymphocytic Leukemia Treated with Lenalidomide.
    Blood. 2020 Dec 23. pii: 474779. doi: 10.1182/blood.2020008609.
    PubMed     Abstract available

  355. FAZIO G, Bardini M, de Lorenzo P, Grioni A, et al
    Blood. 2020 Dec 22. pii: 474771. doi: 10.1182/blood.2020009032.

  356. SLAGER SL, Lanasa MC, Marti GE, Achenbach SJ, et al
    Natural History of Monoclonal B-cell Lymphocytosis (MBL) Among Relatives in Chronic Lymphocytic Leukemia (CLL) Families.
    Blood. 2020 Dec 21. pii: 474760. doi: 10.1182/blood.2020006322.
    PubMed     Abstract available

  357. TARDIVON D, Antoszewski M, Zangger N, Nkosi M, et al
    Notch Signaling Promotes Disease Initiation and Progression in Murine Chronic Lymphocytic Leukemia.
    Blood. 2020 Dec 18. pii: 474750. doi: 10.1182/blood.2020006701.
    PubMed     Abstract available

  358. MIAO H, Kim E, Chen D, Purohit T, et al
    Combinatorial treatment with menin and FLT3 inhibitors induces complete remission in AML models with activating FLT3 mutations.
    Blood. 2020;136:2958-2963.

  359. LIU Y, Panetta JC, Yang W, Karol SE, et al
    Dosing-related saturation of toxicity and accelerated drug clearance with pegaspargase treatment.
    Blood. 2020;136:2955-2958.

  360. HASELAGER MV, Kielbassa K, Ter Burg J, Bax DJC, et al
    Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL.
    Blood. 2020;136:2918-2926.
    PubMed     Abstract available

  361. BULAEVA E, Pellacani D, Nakamichi N, Hammond CA, et al
    MYC-induced human acute myeloid leukemia requires a continuing IL-3/GM-CSF costimulus.
    Blood. 2020;136:2764-2773.
    PubMed     Abstract available

  362. PLATZBECKER U, Kordasti S
    Natural born survivors: the inglorious TP53.
    Blood. 2020;136:2727-2728.

  363. OBERBECK S, Schrader A, Warner K, Jungherz D, et al
    Noncanonical effector functions of the T-memory-like T-PLL cell are shaped by cooperative TCL1A and TCR signaling.
    Blood. 2020;136:2786-2802.
    PubMed     Abstract available

  364. SALLMAN DA, McLemore AF, Aldrich AL, Komrokji RS, et al
    TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype.
    Blood. 2020;136:2812-2823.
    PubMed     Abstract available

  365. STAUBER J, Greally J, Steidl U
    Preleukemic and Leukemic Evolution at the Stem Cell Level.
    Blood. 2020 Dec 4. pii: 474417. doi: 10.1182/blood.2019004397.
    PubMed     Abstract available

  366. TASHAKORI M, Khoury JD
    B acute lymphoblastic leukemia arising during maintenance therapy for multiple myeloma.
    Blood. 2020;136:2720.

  367. LULLA P, Naik S, Vasileiou S, Tzannou I, et al
    Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS post-allogeneic transplant.
    Blood. 2020 Dec 3. pii: 474389. doi: 10.1182/blood.2020009471.
    PubMed     Abstract available

  368. PLEYER C, Ali MA, Cohen JI, Tian X, et al
    Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines.
    Blood. 2020 Dec 1. pii: 474376. doi: 10.1182/blood.2020008758.
    PubMed     Abstract available

    November 2020
  369. CORTES J
    How to manage CML patients with comorbidities.
    Blood. 2020;136:2507-2512.
    PubMed     Abstract available

  370. NADEU F, Royo R, Clot G, Duran-Ferrer M, et al
    IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics.
    Blood. 2020 Nov 19. pii: 474211. doi: 10.1182/blood.2020008311.
    PubMed     Abstract available

  371. RAO S
    RUNX1 and inv(16) are frenemies in AML.
    Blood. 2020;136:2361-2362.

  372. PERL AE
    MLL-menin and FLT3 inhibitors team up for AML.
    Blood. 2020;136:2369-2370.

  373. DZAMA MM, Steiner M, Rausch J, Sasca D, et al
    Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition.
    Blood. 2020;136:2442-2456.
    PubMed     Abstract available

  374. KLINTMAN J, Appleby N, Stamatopoulos B, Ridout K, et al
    Genomic and transcriptomic correlates of Richter's transformation in Chronic Lymphocytic Leukemia.
    Blood. 2020 Nov 18. pii: 474199. doi: 10.1182/blood.2020005650.
    PubMed     Abstract available

  375. SURKA C, Jin L, Mbong N, Lu CC, et al
    CC-90009, a novel cereblon E3 ligase modulator targets acute myeloid leukemia blasts and leukemia stem cells.
    Blood. 2020 Nov 16. pii: 474181. doi: 10.1182/blood.2020008676.
    PubMed     Abstract available

  376. WATANABE A, Miyake K, Nordlund J, Syvanen AC, et al
    Association of aberrant ASNS imprinting with asparaginase sensitivity and chromosomal abnormality in childhood BCP-ALL.
    Blood. 2020;136:2319-2333.
    PubMed     Abstract available

  377. SHARMA S, Pavlasova G, Seda V, Cerna K, et al
    miR-29 Modulates CD40 Signaling in Chronic Lymphocytic Leukemia by Targeting TRAF4: an Axis Affected by BCR inhibitors.
    Blood. 2020 Nov 10. pii: 474127. doi: 10.1182/blood.2020005627.
    PubMed     Abstract available

  378. CHEVILLON F, Clappier E, Arfeuille C, Cayuela JM, et al
    Minimal Residual Disease Quantification in Ovarian Tissue Collected in Patients in Complete Remission of Acute Leukemia.
    Blood. 2020 Nov 10. pii: 474130. doi: 10.1182/blood.2020007782.
    PubMed     Abstract available

  379. HANEKAMP D, Ngai LL, Janssen JJ, van de Loosdrecht AA, et al
    Early assessment of clofarabine effectiveness applying measurable residual disease, including AML stem cells.
    Blood. 2020 Nov 10. pii: 474126. doi: 10.1182/blood.2020007150.

  380. KHANAM T, Sandmann S, Seggewiss J, Ruether CM, et al
    Integrative genomic analysis of pediatric T- cell lymphoblastic lymphoma reveals candidates of clinical significance.
    Blood. 2020 Nov 5. pii: 474099. doi: 10.1182/blood.2020005381.
    PubMed     Abstract available

  381. RIBERA JM, Morgades M, Ciudad J, Montesinos P, et al
    Chemotherapy or Allogeneic Transplantation in High-Risk Philadelphia Chromosome-Negative Adult Lymphoblastic Leukemia.
    Blood. 2020 Nov 4. pii: 474081. doi: 10.1182/blood.2020007311.
    PubMed     Abstract available

  382. GOTTSCHALK HOJFELDT S, Grell K, Abrahamsson J, Lund B, et al
    Relapse risk following truncation of PEG-asparaginase in childhood acute lymphoblastic leukemia.
    Blood. 2020 Nov 4. pii: 474076. doi: 10.1182/blood.2020006583.
    PubMed     Abstract available

    October 2020
  383. ROY A
    A "gut feeling" about precursor B-ALL.
    Blood. 2020;136:1995-1996.

  384. YANG W, Devidas M, Liu Y, Smith C, et al
    Genetics of osteonecrosis in pediatric acute lymphoblastic leukemia and general populations.
    Blood. 2020 Oct 26. pii: 469753. doi: 10.1182/blood.2020008471.

    Rerouting DOT1L inhibitors in leukemia.
    Blood. 2020;136:1900-1901.

    Cost-effectiveness targeting CLL.
    Blood. 2020;136:1896-1898.

  387. PERNER F, Gadrey JY, Xiong Y, Hatton C, et al
    Novel inhibitors of the histone methyltransferase DOT1L show potent antileukemic activity in patient-derived xenografts.
    Blood. 2020;136:1983-1988.

  388. COOK LB, Phillips AA
    How I treat Adult T-cell leukemia/lymphoma.
    Blood. 2020 Oct 19. pii: 469694. doi: 10.1182/blood.2019004045.
    PubMed     Abstract available

  389. BRIVIO E, Locatelli F, Lopez-Yurda M, Malone A, et al
    A Phase I study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study).
    Blood. 2020 Oct 16. pii: 469618. doi: 10.1182/blood.2020007848.
    PubMed     Abstract available

  390. PASSARO D
    Myeloid cells hold the master key for T-ALL spread.
    Blood. 2020;136:1799-1800.

  391. INABA H, Pui CH
    Intensive but tender care for infant ALL.
    Blood. 2020;136:1797-1798.

  392. DUPLOYEZ N, Jamrog LA, Fregona V, Hamelle C, et al
    Germline PAX5 mutation predisposes to familial B acute lymphoblastic leukemia.
    Blood. 2020 Oct 9. pii: 464429. doi: 10.1182/blood.2020005756.
    PubMed     Abstract available

  393. SIDHOM I, Shaaban K, Youssef SH, Ali N, et al
    Reduced-intensity therapy of pediatric lymphoblastic leukemia: Impact of residual disease early in remission induction.
    Blood. 2020 Oct 8. pii: 464272. doi: 10.1182/blood.2020007977.
    PubMed     Abstract available

  394. GODWIN CD, Zhou Y, Othus M, Asmuth MM, et al
    Acute Myeloid Leukemia Measurable Residual Disease Detection by Flow Cytometry in Peripheral Blood Versus Bone Marrow.
    Blood. 2020 Oct 7. pii: 464167. doi: 10.1182/blood.2020006219.

  395. NIEMANN CU, Levin MD, Dubois J, Kersting S, et al
    Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia.
    Blood. 2020 Oct 7. pii: 464169. doi: 10.1182/blood.2020008608.

  396. BARKSDALE B, Leith CP
    CD138+ carcinocythemia mimicking plasma cell leukemia by flow cytometry.
    Blood. 2020;136:1698.

    HHEX expression drives AML development.
    Blood. 2020;136:1575-1576.

  398. TAKEDA R, Asada S, Park SJ, Yokoyama A, et al
    HHEX promotes myeloid transformation in cooperation with mutant ASXL1.
    Blood. 2020;136:1670-1684.
    PubMed     Abstract available

    September 2020
  399. WANG W, Thakral B
    CD123+CD4+CD56+ neoplasm: blastic plasmacytoid dendritic cell neoplasm or acute myeloid leukemia?
    Blood. 2020;136:1565.

  400. THANGAVELU G, Wang C, Loschi M, Saha A, et al
    Repurposing a novel anti-cancer RXR agonist to attenuate acute GVHD and maintain graft-versus-leukemia responses.
    Blood. 2020 Sep 24. pii: 463979. doi: 10.1182/blood.2020005628.
    PubMed     Abstract available

  401. TAYLOR J, Mi X, North K, Binder M, et al
    Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms.
    Blood. 2020;136:1477-1486.
    PubMed     Abstract available

  402. PEPPER M, Tan B
    Acute myeloid leukemia with NPM1 and FLT3 ITD mimicking acute promyelocytic leukemia.
    Blood. 2020;136:1467.

  403. Enshaei A, O'Connor D, Bartram J, et al. A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia. Blood. 2020;135(17):1438-1446.
    Blood. 2020;136:1468.

  404. PINA-OVIEDO S, Thanendrarajan S
    Meningeosis myelomatosis.
    Blood. 2020;136:1466.

  405. STENGER D, Stief TA, Kaeuferle T, Willier S, et al
    Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR.
    Blood. 2020;136:1407-1418.
    PubMed     Abstract available

  406. UY GL, Aldoss I, Foster MC, Sayre PH, et al
    Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia.
    Blood. 2020 Sep 14. pii: 463757. doi: 10.1182/blood.2020007732.
    PubMed     Abstract available

  407. ZHEN T, Cao Y, Ren G, Zhao L, et al
    RUNX1 and CBFbeta-SMMHC transactivate target genes together in abnormal myeloid progenitors for leukemia development.
    Blood. 2020 Sep 14. pii: 463758. doi: 10.1182/blood.2020007747.
    PubMed     Abstract available

  408. VICENTE DUENAS C, Janssen S, Oldenburg M, Auer F, et al
    An intact gut microbiome protects genetically predisposed mice against leukemia.
    Blood. 2020 Sep 10. pii: 463729. doi: 10.1182/blood.2019004381.
    PubMed     Abstract available

  409. KAWABATA KC, Zong H, Meydan C, Wyman S, et al
    BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells.
    Blood. 2020 Sep 10. pii: 463728. doi: 10.1182/blood.2019001745.
    PubMed     Abstract available

  410. WILL B
    No keto for AML stem cells!
    Blood. 2020;136:1219-1221.

    Detonating T-ALL.
    Blood. 2020;136:1218-1219.

  412. YUSUF RZ, Saez B, Sharda A, van Gastel N, et al
    Aldehyde dehydrogenase 3a2 protects AML cells from oxidative death and the synthetic lethality of ferroptosis inducers.
    Blood. 2020;136:1303-1316.
    PubMed     Abstract available

  413. SONG L, Yu B, Yang Y, Liang J, et al
    Identification of functional cooperative mutations of GNAO1 in human acute lymphoblastic leukemia.
    Blood. 2020 Sep 8. pii: 463712. doi: 10.1182/blood.2020005622.
    PubMed     Abstract available

    When CLL meets COVID-19.
    Blood. 2020;136:1115-1116.

  415. MATO AR, Roeker LE, Lamanna N, Allan JN, et al
    Outcomes of COVID-19 in patients with CLL: a multicenter international experience.
    Blood. 2020;136:1134-1143.
    PubMed     Abstract available

  416. FULTANG L, Booth S, Yogev O, Martins da Costa B, et al
    Metabolic engineering against the arginine microenvironment enhances CAR-T cell proliferation and therapeutic activity.
    Blood. 2020;136:1155-1160.
    PubMed     Abstract available

  417. TEACHEY DT, Hunger SP, Loh ML
    Optimizing Therapy in the Modern Age: Differences in Length of Maintenance Therapy in Acute Lymphoblastic Leukemia.
    Blood. 2020 Sep 2. pii: 463610. doi: 10.1182/blood.2020007702.
    PubMed     Abstract available

  418. SHANMUGANATHAN N, Pagani IS, Ross DM, Park S, et al
    Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia.
    Blood. 2020 Sep 1. pii: 463598. doi: 10.1182/blood.2020005514.
    PubMed     Abstract available

  419. XIAO W, Chan A, Waarts MR, Mishra T, et al
    Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1 mutated acute myeloid leukemia.
    Blood. 2020 Sep 1. pii: 463602. doi: 10.1182/blood.2020007897.
    PubMed     Abstract available

  420. FENWARTH L, Thomas X, de Botton S, Duployez N, et al
    A Personalized Approach to Guide Allogeneic Stem Cell Transplantation in Younger Adults with Acute Myeloid Leukemia.
    Blood. 2020 Sep 1. pii: 463599. doi: 10.1182/blood.2020005524.
    PubMed     Abstract available

    August 2020
  421. TAN Y, Wang X, Song H, Zhang Y, et al
    A PML/RARalpha direct target atlas redefines transcriptional deregulation in acute promyelocytic leukemia.
    Blood. 2020 Aug 27. pii: 463523. doi: 10.1182/blood.2020005698.
    PubMed     Abstract available

  422. WANG HY, Tzachanis D
    Extramedullary early T-cell precursor acute lymphoblastic lymphoma presenting as blast crisis of CML.
    Blood. 2020;136:1112.

  423. LUEDKE C, Rein L
    Transformation to erythroblastic sarcoma from myeloid neoplasm with PCM1-JAK2.
    Blood. 2020;136:1113.

  424. DEWOLF S, Tallman MS
    How I treat relapsed or refractory AML.
    Blood. 2020;136:1023-1032.
    PubMed     Abstract available

  425. FANG H, Xu J
    Blastoid plasma cell leukemia mimicking acute leukemia.
    Blood. 2020;136:1012.

  426. LIU H
    NUP98 rearrangement in B lymphoblastic leukemia with hyperdiploidy.
    Blood. 2020;136:1011.

  427. MALINGE S
    SNAIL trail in myeloid malignancies.
    Blood. 2020;136:920-921.

    Deletions in BCP-ALL result in a TAD more FLT3.
    Blood. 2020;136:919-920.

  429. CARMICHAEL CL, Wang J, Nguyen T, Kolawole O, et al
    The EMT modulator SNAI1 contributes to AML pathogenesis via its interaction with LSD1.
    Blood. 2020;136:957-973.
    PubMed     Abstract available

  430. ALBERTI-SERVERA L, Demeyer S, Govaerts I, Swings T, et al
    Single-cell DNA amplicon sequencing reveals clonal heterogeneity and evolution in T-cell acute lymphoblastic leukemia.
    Blood. 2020 Aug 18. pii: 463329. doi: 10.1182/blood.2020006996.
    PubMed     Abstract available

  431. JOLLY CJ, Pimanda JE
    Titans awake: HMAs for virus-driven ATL.
    Blood. 2020;136:777-779.

  432. WATANABE T, Yamashita S, Ureshino H, Kamachi K, et al
    Targeting aberrant DNA hypermethylation as a driver of ATL leukemogenesis by using the new oral demethylating agent OR-2100.
    Blood. 2020;136:871-884.
    PubMed     Abstract available

    Erythroleukemia: all roads lead to GATA1?
    Blood. 2020;136:648-649.

  434. FAGNAN A, Bagger FO, Pique-Borras MR, Ignacimouttou C, et al
    Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers.
    Blood. 2020;136:698-714.
    PubMed     Abstract available

  435. GARCIA-MANERO G, Griffiths EA, Steensma DP, Roboz GJ, et al
    Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study.
    Blood. 2020;136:674-683.
    PubMed     Abstract available

  436. RODERICK JE, Gallagher KM, Murphy LC, O'Connor KW, et al
    Prostaglandin E2 stimulates cAMP signaling and re-sensitizes human leukemia cells to glucocorticoid-induced cell death.
    Blood. 2020 Aug 5. pii: 461709. doi: 10.1182/blood.2020005712.
    PubMed     Abstract available

    July 2020
  437. YOSHINO S, Yokoyama T, Sunami Y, Takahara T, et al
    Trib1 promotes acute myeloid leukemia progression by modulating the transcriptional programs of Hoxa9.
    Blood. 2020 Jul 30. pii: 461620. doi: 10.1182/blood.2019004586.
    PubMed     Abstract available

  438. CARROLL M
    A common protein target for an uncommon subtype of AML.
    Blood. 2020;136:377-378.

  439. BEAUMONT AL, Suner L
    Drug-induced aseptic meningitis in a Ph+ ALL patient with meningeal involvement.
    Blood. 2020;136:520.

  440. ASSAF N, Terre C
    Double translocation or gene insertion? A BCR/ABL1 fusion in Philadelphia-negative CML.
    Blood. 2020;136:521.

  441. SAAD M, Loh KP, Tooze JA, Pardee TS, et al
    Geriatric assessment and survival among older adults receiving post-remission therapy for acute myeloid leukemia.
    Blood. 2020 Jul 22. pii: 461543. doi: 10.1182/blood.2020005498.

  442. NISHII R, Baskin-Doerfler R, Yang W, Oak N, et al
    Molecular Basis of ETV6-Mediated Predisposition to Childhood Acute Lymphoblastic Leukemia.
    Blood. 2020 Jul 21. pii: 461432. doi: 10.1182/blood.2020006164.
    PubMed     Abstract available

  443. BRADY SW, Ma X, Zhou BS, Pui CH, et al
    Response to "Pre-existing or Therapy-induced Mutations in Relapsed Acute Lymphoblastic Leukemia?"
    Blood. 2020 Jul 20. pii: 461427. doi: 10.1182/blood.2020008107.

  444. BLOUIN JM, Ged C, Lalanne M, Lamrissi-Garcia I, et al
    Iron chelation rescues hemolytic anemia and skin photosensitivity in congenital erythropoietic porphyria.
    Blood. 2020 Jul 17. pii: 461423. doi: 10.1182/blood.2020006037.
    PubMed     Abstract available

  445. PIVA E, Tosato F
    Promyelocytic leukemia with basophil-like granules.
    Blood. 2020;136:372.

  446. STOCK W
    Thrombosis in ALL: a risk without clear mitigation.
    Blood. 2020;136:264-265.

  447. MOLINA O, Vinyoles M, Granada I, Roca-Ho H, et al
    Impaired condensin complex and Aurora B kinase underlie mitotic and chromosomal defects in hyperdiploid B-cell ALL.
    Blood. 2020;136:313-327.
    PubMed     Abstract available

  448. MUJAHED H, Miliara S, Neddermeyer A, Bengtzen S, et al
    AML displays increased CTCF occupancy associated with aberrant gene expression and transcription factor binding.
    Blood. 2020;136:339-352.
    PubMed     Abstract available

  449. TSURUTA Y, Karube K
    Hodgkin and Reed-Sternberg-like cells infected with human T-cell leukemia virus type 1.
    Blood. 2020;136:257.

  450. Garzon R, Savona M, Baz R, et al. A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia. Blood. 2017;129(24):3165-3174.
    Blood. 2020;136:259.

  451. LYAPICHEV KA, Jelloul FZ
    Simultaneous bone marrow involvement by CLL/SLL and LEF1/cyclin D1-positive metastatic melanoma.
    Blood. 2020;136:258.

  452. TOMIZAWA D, Miyamura T, Imamura T, Watanabe T, et al
    A risk-stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial.
    Blood. 2020 Jul 7. pii: 461277. doi: 10.1182/blood.2019004741.
    PubMed     Abstract available

  453. FRIEDRICH C, Barreau S
    A splenic lymphoma/leukemia with a spontaneous blast decrease without treatment.
    Blood. 2020;136:148.

    Occupy BTK: the key to controlling CLL.
    Blood. 2020;136:4-6.

  455. LICHT JD
    Oncogenesis by E2A-PBX1 in ALL: RUNX and more.
    Blood. 2020;136:3-4.

  456. KHAN DH, Mullokandov M, Wu Y, Voisin V, et al
    Mitochondrial carrier homolog 2 is necessary for AML survival.
    Blood. 2020;136:81-92.
    PubMed     Abstract available

  457. SUN C, Nierman P, Kendall EK, Cheung J, et al
    Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib.
    Blood. 2020;136:93-105.
    PubMed     Abstract available

  458. FALINI B, Brunetti L, Sportoletti P, Martelli MP, et al
    NPM1-mutated acute myeloid leukemia: from bench to bedside.
    Blood. 2020 Jul 1. pii: 461241. doi: 10.1182/blood.2019004226.
    PubMed     Abstract available

    June 2020
  459. GAYNON PS, Orgel E, Ji L
    Pre-existing or Therapy-induced Mutations in Relapsed Acute Lymphoblastic Leukemia?
    Blood. 2020 Jun 30. pii: 461230. doi: 10.1182/blood.2020005258.

  460. BULAEVA E, Pellacani D, Nakamichi N, Hammond CA, et al
    MYC-induced human acute myeloid leukemia requires a continuing IL3/GM-CSF co-stimulus.
    Blood. 2020 Jun 29. pii: 461224. doi: 10.1182/blood.2020006374.
    PubMed     Abstract available

  461. HUNGER SP, Raetz E
    How I Treat Relapsed Acute Lymphoblastic Leukemia in the Pediatric Population.
    Blood. 2020 Jun 26. pii: 461194. doi: 10.1182/blood.2019004043.
    PubMed     Abstract available

  462. GIOTOPOULOS G, Huntly BJP
    CML: new tools to answer old questions.
    Blood. 2020;135:2327-2328.

  463. STANKOVIC T, Kwok M
    Genetics in the era of targeted CLL therapy.
    Blood. 2020;135:2333-2334.

  464. GEYER HL, Gazelka H, Mesa R
    How I treat pain in hematologic malignancies safely with opioid therapy.
    Blood. 2020;135:2354-2364.
    PubMed     Abstract available

  465. TAUSCH E, Schneider C, Robrecht S, Zhang C, et al
    Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax.
    Blood. 2020;135:2402-2412.
    PubMed     Abstract available

  466. MATSUMURA T, Nakamura-Ishizu A, Muddineni SSNA, Tan DQ, et al
    Hematopoietic stem cells acquire survival advantage by loss of RUNX1 methylation identified in familial leukemia.
    Blood. 2020 Jun 23. pii: 461100. doi: 10.1182/blood.2019004292.
    PubMed     Abstract available

  467. CUNEO A, Scarfo L, Reda G, Varettoni M, et al
    Blood. 2020 Jun 19. pii: 461059. doi: 10.1182/blood.2020006854.

  468. RAFFEL S, Klimmeck D, Falcone M, Demir A, et al
    Quantitative proteomics reveals specific metabolic features of Acute Myeloid Leukemia stem cells.
    Blood. 2020 Jun 18. pii: 461031. doi: 10.1182/blood.2019003654.
    PubMed     Abstract available

  469. Setd2 deficiency accelerated MDS-related leukemia.
    Blood. 2020;135:2326.

  470. CRUZ HERNANDEZ D, Metzner M, de Groot AP, Usukhbayar B, et al
    Sensitive, Rapid Diagnostic Test For Transient Abnormal Myelopoiesis and Myeloid Leukemia of Down Syndrome.
    Blood. 2020 Jun 18. pii: 461036. doi: 10.1182/blood.2020005610.

  471. BROWN JR
    Inverting the BTK-BCL2 order.
    Blood. 2020;135:2205-2207.

  472. GRANTS JM, Wegrzyn J, Hui T, O'Neill K, et al
    Altered microRNA expression links IL6 and TNF-induced inflammaging with myeloid malignancy in humans and mice.
    Blood. 2020;135:2235-2251.
    PubMed     Abstract available

  473. LIN VS, Lew TE, Handunnetti SM, Blombery P, et al
    BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax.
    Blood. 2020;135:2266-2270.
    PubMed     Abstract available

  474. CHEN BY, Song J, Hu CL, Chen SB, et al
    SETD2 deficiency accelerates MDS-associated leukemogenesis via S100a9 in NHD13 mice and predicts poor prognosis in MDS.
    Blood. 2020;135:2271-2285.
    PubMed     Abstract available

    ON TRacK towards novel targets in leukemia.
    Blood. 2020;135:2117-2119.

  476. LOWENBERG B, Huls G
    The long road: improving outcome in elderly "unfit" AML?
    Blood. 2020;135:2114-2115.

  477. LUCAS F, Larkin K, Gregory CT, Orwick S, et al
    Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations.
    Blood. 2020;135:2192-2195.

  478. WEI AH, Montesinos P, Ivanov V, DiNardo CD, et al
    Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.
    Blood. 2020;135:2137-2145.
    PubMed     Abstract available

  479. DIRAL E, Mori S, Antolini L, Abruzzese E, et al
    Increased tumor burden in Chronic Myeloid Leukemia patients after 36 months of imatinib discontinuation.
    Blood. 2020 Jun 9. pii: 460734. doi: 10.1182/blood.2019004371.

  480. PATEL K, Isufi I, Kothari S, Davidoff AJ, et al
    Cost-Effectiveness of First-Line Ibrutinib versus Third-Line in Patients with Untreated Chronic Lymphocytic Leukemia.
    Blood. 2020 Jun 9. pii: 460741. doi: 10.1182/blood.2020004922.
    PubMed     Abstract available

  481. Norsworthy KJ, Bird ST, Avagyan A, et al. Second cancers in adults with acute promyelocytic leukemia (APL) treated with or without arsenic trioxide (ATO): a SEER-Medicare analysis [abstract]. Blood. 2019;134(suppl 1). Abstract 3497.
    Blood. 2020;135:2111.

  482. RATNER L
    Predicting the future: adult T-cell leukemia.
    Blood. 2020;135:2013-2014.

  483. ROLLIG C, Kramer M, Schliemann C, Mikesch JH, et al
    Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?
    Blood. 2020 Jun 4. pii: 460669. doi: 10.1182/blood.2019004583.
    PubMed     Abstract available

  484. AN J, Ko M
    Decoding ribosomes to keep growing (in AML).
    Blood. 2020;135:2015-2016.

  485. SAINI NY, Marin D, Ledesma C, Delgado R, et al
    Impact of TKI maintenance post-allogeneic transplant in Philadelphia positive acute lymphoblastic leukemia.
    Blood. 2020 Jun 3. pii: 460671. doi: 10.1182/blood.2019004685.

  486. TRAN QUANG C, Zaniboni B, Humeau R, Lengline E, et al
    Preclinical Efficacy of Humanized, non-FcgammaR Binding Anti-CD3 Antibodies in T-cell Acute Lymphoblastic Leukemia.
    Blood. 2020 Jun 1. pii: 460600. doi: 10.1182/blood.2019003801.
    PubMed     Abstract available

    May 2020

  487. Passet M, Boissel N, Sigaux F, et al; Group for Research on Adult ALL (GRAALL). PAX5 P80R mutation identifies a novel subtype of B-cell precursor acute lymphoblastic leukemia with favorable outcome. Blood. 2019;133(3):280-284.
    Blood. 2020;135:2011.

  488. NEGRETE D, Huang Q
    A striking case of iatrogenic granulocytic nuclear abnormality in the bone marrow.
    Blood. 2020;135:2010.

  489. SCHRATZ KE, Haley L, Danoff SK, Blackford AL, et al
    Cancer spectrum and outcomes in the Mendelian short telomere syndromes.
    Blood. 2020;135:1946-1956.
    PubMed     Abstract available

  490. ABDO C, Thonier F, Simonin M, Kaltenbach S, et al
    Caution encouraged in NGS immunogenetic analyses in Acute Lymphoblastic Leukemia.
    Blood. 2020 May 21. pii: 456040. doi: 10.1182/blood.2020005613.

  491. SUNG PJ, Babushok DV
    Born to RUNX1.
    Blood. 2020;135:1824-1825.

  492. TAM CS, Seymour JF
    A predictive tool for early-stage CLL.
    Blood. 2020;135:1820-1821.

  493. SIMON L, Spinella JF, Yao CY, Lavallee VP, et al
    High frequency of germline RUNX1 mutations in patients with RUNX1-mutated AML.
    Blood. 2020;135:1882-1886.
    PubMed     Abstract available

  494. MENSSEN AJ, Walter MJ
    Genetics of Progression from MDS to Secondary Leukemia.
    Blood. 2020 May 19. pii: 456027. doi: 10.1182/blood.2019000942.
    PubMed     Abstract available

  495. SUN L, Babushok DV
    Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria.
    Blood. 2020 May 19. pii: 456026. doi: 10.1182/blood.2019000940.
    PubMed     Abstract available

  496. DUNBAR A, Rampal R, Levine RL
    Secondary leukemia to myeloproliferative neoplasms.
    Blood. 2020 May 19. pii: 456028. doi: 10.1182/blood.2019000943.
    PubMed     Abstract available

  497. SOULIER J
    Introduction to a review series on secondary leukemia.
    Blood. 2020 May 19. pii: 456030. doi: 10.1182/blood.2019004171.

  498. SCOTT HS, Hahn CN, Brown AL
    Secondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA).
    Blood. 2020 May 19. pii: 456025. doi: 10.1182/blood.2019000937.
    PubMed     Abstract available

  499. JELINEK T, Zuchnicka J
    Peripheral T-cell lymphoma, NOS, with rapidly progressing leukocytosis mimicking acute lymphoblastic leukemia.
    Blood. 2020;135:1816.

  500. GEBRU MT, Atkinson JM, Young M, Zhang L, et al
    Glucocorticoids enhance the anti-leukemic activity of FLT3 inhibitors in FLT3 mutant acute myeloid leukemia.
    Blood. 2020 May 12. pii: 455305. doi: 10.1182/blood.2019003124.
    PubMed     Abstract available

  501. SONG C, Ge Z, Ding Y, Tan BH, et al
    IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity inhigh-risk B-cell acute lymphoblastic leukemia.
    Blood. 2020 May 12. pii: 455304. doi: 10.1182/blood.2019002655.
    PubMed     Abstract available

  502. TULSTRUP M, Moriyama T, Jiang C, Grosjean M, et al
    Effects of germline variants in DHFR and FPGS on methotrexate metabolism and relapse of leukemia.
    Blood. 2020 May 11. pii: 455060. doi: 10.1182/blood.2020005064.
    PubMed     Abstract available

  503. YANG M, Safavi S, Woodward EL, Duployez N, et al
    13q12.2 deletions in acute lymphoblastic leukemia lead to upregulation of FLT3 through enhancer hijacking.
    Blood. 2020 May 8. pii: 454973. doi: 10.1182/blood.2019004684.
    PubMed     Abstract available

  504. KATER AP, Melenhorst JJ
    CAR-T and ibrutinib vs CLL: sequential or simultaneous?
    Blood. 2020;135:1611-1612.

  505. GERBY B, Hoang T
    A targetable cue in T-cell malignancy.
    Blood. 2020;135:1616-1617.

  506. RONNER L, Podoltsev N, Gotlib J, Heaney ML, et al
    Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis.
    Blood. 2020;135:1696-1703.
    PubMed     Abstract available

  507. GAUTHIER J, Hirayama AV, Purushe J, Hay KA, et al
    Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure.
    Blood. 2020;135:1650-1660.
    PubMed     Abstract available

    April 2020
  508. DE DOMINICI M, Porazzi P, Xiao Y, Chao A, et al
    Selective inhibition of Ph-positive ALL cell growth through kinase-dependent and -independent effects by CDK6-specific PROTACs.
    Blood. 2020;135:1560-1573.
    PubMed     Abstract available

  509. SCHMOELLERL J, Barbosa IAM, Eder T, Brandstoetter T, et al
    CDK6 is an essential direct target of NUP98-fusion proteins in acute myeloid leukemia.
    Blood. 2020 Apr 28. pii: 454667. doi: 10.1182/blood.2019003267.
    PubMed     Abstract available

  510. LONG J, Jia MY, Fang WY, Chen XJ, et al
    FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.
    Blood. 2020;135:1472-1483.
    PubMed     Abstract available

  511. ENSHAEI A, O'Connor D, Bartram J, Hancock J, et al
    A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia.
    Blood. 2020;135:1438-1446.
    PubMed     Abstract available

  512. KRAUSE DS
    The Fox(o) and the HDAC.
    Blood. 2020;135:1416-1417.

    Go with the flow: simplified MRD in LMIC ALL.
    Blood. 2020;135:1414-1415.

  514. COOK LBM, Rowan AG
    CD28 fusions: an opportunity for young ATL?
    Blood. 2020;135:1415-1416.

  515. LIU H, Hu S
    Acute leukemic variant of blastic plasmacytoid dendritic cell neoplasm at initial presentation.
    Blood. 2020;135:1506.

  516. WIERDA WG, Tambaro FP
    How I manage CLL with venetoclax-based treatments.
    Blood. 2020;135:1421-1427.
    PubMed     Abstract available

  517. CLESHAM K, Rao V, Bartram J, Ancliff P, et al
    Blinatumomab for infant acute lymphoblastic leukemia.
    Blood. 2020;135:1501-1504.

  518. YOSHIDA N, Shigemori K, Donaldson N, Trevisani C, et al
    Genomic landscape of young ATLL patients identifies frequent targetable CD28 fusions.
    Blood. 2020;135:1467-1471.
    PubMed     Abstract available

  519. ORVAIN C, Balsat M, Tavernier E, Marolleau JP, et al
    Thromboembolism Prophylaxis in Adult Patients with Acute Lymphoblastic Leukemia Treated in the GRAALL-2005 Study.
    Blood. 2020 Apr 22. pii: 454452. doi: 10.1182/blood.2020004919.
    PubMed     Abstract available

  520. MARRA A, Martino G
    Placental myeloid sarcoma.
    Blood. 2020;135:1410.

  521. HAROCHE J, Cohen-Aubart F, Amoura Z
    Erdheim-Chester disease.
    Blood. 2020;135:1311-1318.
    PubMed     Abstract available

  522. SCHETELIG J, Baldauf H, Heidenreich F, Massalski C, et al
    External validation of models for KIR2DS1/KIR3DL1-informed selection of hematopoietic cell donors fails.
    Blood. 2020;135:1386-1395.
    PubMed     Abstract available

  523. PATNAIK MM, Sallman DA, Mangaonkar A, Heuer R, et al
    Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia (CMML).
    Blood. 2020 Apr 15. pii: 454390. doi: 10.1182/blood.2019004352.

  524. PI WC, Wang J, Shimada M, Lin JW, et al
    E2A-PBX1 functions as a coactivator for RUNX1 in acute lymphoblastic leukemia.
    Blood. 2020 Apr 10. pii: 454360. doi: 10.1182/blood.2019003312.
    PubMed     Abstract available

  525. HSU A, Freeman N
    The fertile field of "isomopic" immune dysregulation as a nidus for lymphoproliferative disorders.
    Blood. 2020;135:1303.

  526. SAENZ DT, Fiskus W, Mill CP, Perera D, et al
    Mechanistic basis and efficacy of targeting the beta-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors.
    Blood. 2020;135:1255-1269.
    PubMed     Abstract available

  527. CONDOLUCI A, Terzi di Bergamo L, Langerbeins P, Hoechstetter MA, et al
    International Prognostic Score for Asymptomatic Early-stage Chronic Lymphocytic Leukemia.
    Blood. 2020 Apr 8. pii: 454292. doi: 10.1182/blood.2019003453.
    PubMed     Abstract available

  528. LIN H, Rothe K, Chen M, Wu A, et al
    The miR-185/PAK6 Axis Predicts Therapy Response and Regulates Survival of Drug-Resistant Leukemic Stem Cells in CML.
    Blood. 2020 Apr 8. pii: 454304. doi: 10.1182/blood.2019003636.
    PubMed     Abstract available

  529. SIMKINS A, Dunleavy K
    Tackling Burkitt when it's back.
    Blood. 2020;135:1078-1080.

  530. GHANNAM JY, Xu X, Maric I, Dillon L, et al
    Baseline TP53 mutations in adults with SCD developing myeloid malignancy following hematopoietic cell transplantation.
    Blood. 2020;135:1185-1188.

    March 2020
  531. OTTEMA S, Mulet-Lazaro R, Beverloo HB, Erpelinck CAJ, et al
    Atypical 3q26/MECOM rearrangements genocopy inv(3)/t(3;3) in acute myeloid leukemia.
    Blood. 2020 Mar 27. pii: 454178. doi: 10.1182/blood.2019003701.
    PubMed     Abstract available

  532. GANG EJ, Kim HN, Hsieh YT, Ruan Y, et al
    Integrin alpha6 mediates drug resistance of acute lymphoblastic B-cell leukemia.
    Blood. 2020 Mar 27. pii: 454180. doi: 10.1182/blood.2019001417.
    PubMed     Abstract available

  533. KLEIN E, Bidet A
    MYC and KMT2A multiple extra copies in acute myeloid leukemia.
    Blood. 2020;135:1070.

  534. JINNOUCHI F, Yamauchi T, Yurino A, Nunomura T, et al
    Establishment of a human SIRPA knock-in xenograft mouse model to study human hematopoietic and cancer stem cells.
    Blood. 2020 Mar 23. pii: 452764. doi: 10.1182/blood.2019002194.
    PubMed     Abstract available

  535. CHIANG MY
    Tearing ATL apart to find HTLV's sinister plans.
    Blood. 2020;135:887-889.

  536. HASSERJIAN RP, Steensma DP, Graubert TA, Ebert BL, et al
    Clonal Hematopoiesis and Measurable Residual Disease Assessment in Acute Myeloid Leukemia.
    Blood. 2020 Mar 13. pii: 452698. doi: 10.1182/blood.2019004770.
    PubMed     Abstract available

  537. ABRISQUETA P, Bosch F
    Venetoclax-obinutuzumab: harnessing complexity.
    Blood. 2020;135:788-789.

    BCL-2 inhibition and AML: can we best Darwin?
    Blood. 2020;135:781-782.

  539. DINARDO CD, Tiong IS, Quaglieri A, MacRaild S, et al
    Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.
    Blood. 2020;135:791-803.
    PubMed     Abstract available

  540. CHONG SJF, Davids MS
    Breaking through BCL-2 inhibition in CLL.
    Blood. 2020;135:709-711.

  541. DAVER N
    A bispecific approach to improving CAR T cells in AML.
    Blood. 2020;135:703-704.

  542. FU CL, Diacovo MJ
    Niemann-Pick disease with isolated leukemic nonnodal mantle cell lymphoma of the spleen.
    Blood. 2020;135:778.

  543. GOTTSCHALK A, Glauche I, Cicconi S, Clark RE, et al
    Molecular monitoring during dose reduction predicts recurrence after TKI cessation in CML.
    Blood. 2020;135:766-769.

    February 2020
  544. DILLON R, Hills R, Freeman S, Potter N, et al
    Molecular MRD status and outcome after transplantation in NPM1-mutated AML.
    Blood. 2020;135:680-688.
    PubMed     Abstract available

  545. DUFVA O, Koski J, Maliniemi P, Ianevski A, et al
    Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity.
    Blood. 2020;135:597-609.
    PubMed     Abstract available

  546. SOVERINI S, Bavaro L, De Benedittis C, Martelli M, et al
    Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study.
    Blood. 2020;135:534-541.
    PubMed     Abstract available

  547. DE SMEDT R, Morscio J, Reunes L, Roels J, et al
    Targeting cytokine and therapy induced PIM1 activation in T-cell acute lymphoblastic leukemia and lymphoma.
    Blood. 2020 Feb 13. pii: 452489. doi: 10.1182/blood.2019003880.
    PubMed     Abstract available

  548. KAGOTHO E, Chang H
    CML in megakaryocytic transformation and extramedullary infiltration.
    Blood. 2020;135:514.

  549. STRATI P, Schlette EJ, Solis Soto LM, Duenas DE, et al
    Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors.
    Blood. 2020;135:510-513.

  550. CIUREA SO, Kongtim P, Varma A, Rondon G, et al
    Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?
    Blood. 2020;135:449-452.
    PubMed     Abstract available

  551. KWOK M, Oldreive C, Rawstron AC, Goel A, et al
    Integrative analysis of spontaneous CLL regression highlights genetic and microenvironmental interdependency in CLL.
    Blood. 2020;135:411-428.
    PubMed     Abstract available

    January 2020
  552. PAN J, Zuo S, Deng B, Xu X, et al
    Sequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALL.
    Blood. 2020;135:387-391.

  553. FABRE MA, McKerrell T, Zwiebel M, Vijayabaskar MS, et al
    Concordance for clonal hematopoiesis is limited in elderly twins.
    Blood. 2020;135:269-273.
    PubMed     Abstract available

  554. HANSEN JW, Pedersen DA, Larsen LA, Husby S, et al
    Clonal hematopoiesis in elderly twins: concordance, discordance, and mortality.
    Blood. 2020;135:261-268.
    PubMed     Abstract available

  555. MEYER SE
    MicroRNA immunomodulating therapeutics.
    Blood. 2020;135:155-156.

  556. HALE DA, Krause JR
    Unexpected lymph node finding in a patient with essential thrombocythemia.
    Blood. 2020;135:154.

  557. MORSCIO J, Van Vlierberghe P
    Chemotherapy at the wheel of ALL relapse.
    Blood. 2020;135:4-5.

  558. SWANSON HD, Panetta JC, Barker PJ, Liu Y, et al
    Predicting success of desensitization after pegaspargase allergy.
    Blood. 2020;135:71-75.

  559. LEVIS M, Shi W, Chang K, Laing C, et al
    FLT3 inhibitors added to induction therapy induce deeper remissions.
    Blood. 2020;135:75-78.

  560. WANG N, Hu X, Cao W, Li C, et al
    Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies.
    Blood. 2020;135:17-27.
    PubMed     Abstract available

    December 2019
  561. GARDNER RA, Ceppi F, Rivers J, Annesley C, et al
    Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy.
    Blood. 2019;134:2149-2158.
    PubMed     Abstract available

    October 2019
  562. THANGAVELU G, Du J, Paz KG, Loschi M, et al
    Inhibition of Inositol kinase B controls acute and chronic graft-versus-host disease.
    Blood. 2019 Oct 15. pii: 387148. doi: 10.1182/blood.2019000032.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.